<?xml version="1.0" encoding="UTF-8"?>
<search_results count="327386">
  <query>ALL</query>
  <!-- Additional study fields may be added over time -->
  <study rank="327001">
    <nct_id>NCT00000462</nct_id>
    <title>Bypass Angioplasty Revascularization Investigation (BARI)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Angina Pectoris</condition>
      <condition>Cardiovascular Diseases</condition>
      <condition>Coronary Disease</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Heart Diseases</condition>
      <condition>Myocardial Ischemia</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">angioplasty, transluminal, percutaneous coronary</intervention>
      <intervention type="Procedure">coronary artery bypass</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Heart, Lung, and Blood Institute (NHLBI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>51</other_id>
      <other_id>U01HL038610</other_id>
    </other_ids>
    <start_date>April 1987</start_date>
    <completion_date>November 2004</completion_date>
    <study_first_posted>October 28, 1999</study_first_posted>
    <last_update_posted>May 13, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000462</url>
  </study>
  <study rank="327002">
    <nct_id>NCT00000461</nct_id>
    <title>Harvard Atherosclerosis Reversibility Project (HARP)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Coronary Disease</condition>
      <condition>Heart Diseases</condition>
      <condition>Myocardial Ischemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pravastatin</intervention>
      <intervention type="Drug">niacin</intervention>
      <intervention type="Drug">cholestyramine</intervention>
      <intervention type="Drug">gemfibrozil</intervention>
      <intervention type="Drug">fatty acids, omega-3</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Heart, Lung, and Blood Institute (NHLBI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>50</other_id>
      <other_id>R01HL036392</other_id>
    </other_ids>
    <start_date>December 1986</start_date>
    <completion_date>November 1992</completion_date>
    <study_first_posted>October 28, 1999</study_first_posted>
    <last_update_posted>March 16, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000461</url>
  </study>
  <study rank="327003">
    <nct_id>NCT00000460</nct_id>
    <title>Training Levels Comparison Trial</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Coronary Disease</condition>
      <condition>Heart Diseases</condition>
      <condition>Myocardial Ischemia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Low intensity exercise</intervention>
      <intervention type="Behavioral">High intensity exercise</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>30 Years</min_age>
    <max_age>67 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>49</other_id>
      <other_id>R01HL037597</other_id>
    </other_ids>
    <start_date>December 1986</start_date>
    <primary_completion_date>March 1991</primary_completion_date>
    <completion_date>March 1991</completion_date>
    <study_first_posted>October 28, 1999</study_first_posted>
    <last_update_posted>January 6, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000460</url>
  </study>
  <study rank="327004">
    <nct_id>NCT00000459</nct_id>
    <title>Dietary Intervention Study in Children (DISC)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Heart Diseases</condition>
      <condition>Hypercholesterolemia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">diet, fat-restricted</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Heart, Lung, and Blood Institute (NHLBI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>10 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>48</other_id>
      <other_id>U01HL037947</other_id>
      <other_id>U01HL037948</other_id>
      <other_id>U01HL037954</other_id>
      <other_id>U01HL037962</other_id>
      <other_id>U01HL037966</other_id>
      <other_id>U01HL037975</other_id>
      <other_id>U01HL038110</other_id>
    </other_ids>
    <start_date>December 1986</start_date>
    <completion_date>January 1999</completion_date>
    <study_first_posted>October 28, 1999</study_first_posted>
    <last_update_posted>May 5, 2016</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000459</url>
  </study>
  <study rank="327005">
    <nct_id>NCT00004500</nct_id>
    <title>Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Meconium Aspiration</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lucinactant</intervention>
      <intervention type="Other">Standard Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Days Receiving Mechanical Ventilation (MV)</outcome_measure>
      <outcome_measure>Incidence of Death</outcome_measure>
      <outcome_measure>Number of Participants With Air Leaks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Windtree Therapeutics</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>48 Hours</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KL4-MAS-03</other_id>
      <other_id>FD-R-001938</other_id>
    </other_ids>
    <start_date>March 2000</start_date>
    <primary_completion_date>November 2002</primary_completion_date>
    <completion_date>November 2004</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <results_first_posted>May 1, 2012</results_first_posted>
    <last_update_posted>May 3, 2012</last_update_posted>
    <locations>
      <location>Discovery Laboratories, Inc., Warrington, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004500</url>
  </study>
  <study rank="327006">
    <nct_id>NCT00004498</nct_id>
    <title>Phase I Study of Adenoviral Vector Mediated Gene Transfer for Ornithine Transcarbamylase in Adults With Partial Ornithine Transcarbamylase Deficiency</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ornithine Transcarbamylase Deficiency Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">Adenoviral Vector-Mediated Gene Transfer</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>69 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14290</other_id>
      <other_id>UPSM-FDR001529</other_id>
    </other_ids>
    <start_date>July 1998</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004498</url>
  </study>
  <study rank="327007">
    <nct_id>NCT00004497</nct_id>
    <title>Phase III Randomized Study of UT-15 in Patients With Primary Pulmonary Hypertension</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">UT-15</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>United Therapeutics</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14287</other_id>
      <other_id>UTC-FDR001545</other_id>
      <other_id>UTC-P01-04</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States</location>
      <location>Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States</location>
      <location>University of Maryland Medical System, Baltimore, Maryland, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Columbia University College of Physicians and Surgeons, New York, New York, United States</location>
      <location>United Therapeutics Corporation, Research Triangle Park, North Carolina, United States</location>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004497</url>
  </study>
  <study rank="327008">
    <nct_id>NCT00004496</nct_id>
    <title>Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Renal Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alpha-melanocyte stimulating hormone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Texas</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14286</other_id>
      <other_id>UTSMC-FDR001552</other_id>
      <other_id>UTSMC-129447100</other_id>
    </other_ids>
    <start_date>February 1999</start_date>
    <completion_date>September 2003</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States</location>
      <location>Baylor University Medical Center, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004496</url>
  </study>
  <study rank="327009">
    <nct_id>NCT00004495</nct_id>
    <title>Randomized Study of Folic Acid Therapy for Hyperhomocysteinemia in Patients With End Stage Renal Disease Receiving Hemodialysis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End Stage Renal Disease</condition>
      <condition>Hyperhomocysteinemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cyanocobalamin</intervention>
      <intervention type="Drug">folic acid</intervention>
      <intervention type="Drug">pyridoxine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Georgetown University</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14276</other_id>
      <other_id>GUMC-FDR001544</other_id>
    </other_ids>
    <start_date>June 1999</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Georgetown University Medical Center, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004495</url>
  </study>
  <study rank="327010">
    <nct_id>NCT00004494</nct_id>
    <title>Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sepsis</condition>
      <condition>Respiratory Distress Syndrome</condition>
      <condition>Respiratory Distress Syndrome, Adult</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">vasoactive intestinal peptide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Stony Brook University</lead_sponsor>
      <collaborator>State University of New York</collaborator>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14275</other_id>
      <other_id>SUNY-SB-FDR001488</other_id>
      <other_id>SUNY-SB-96-077</other_id>
      <other_id>SUNY-SB-98-2606</other_id>
      <other_id>FD-R-0001488</other_id>
    </other_ids>
    <start_date>September 1998</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 8, 2013</last_update_posted>
    <locations>
      <location>Veterans Affairs Medical Center - Northport, Northport, New York, United States</location>
      <location>State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004494</url>
  </study>
  <study rank="327011">
    <nct_id>NCT00004493</nct_id>
    <title>Phase II Pilot Randomized Study of Sodium Dichloroacetate in Patients With Congenital Lactic Acidemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lactic Acidosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sodium dichloroacetate</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14274</other_id>
      <other_id>UCSD-FDR001481</other_id>
    </other_ids>
    <start_date>September 1998</start_date>
    <completion_date>September 2003</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>University of California San Diego School of Medicine, La Jolla, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004493</url>
  </study>
  <study rank="327012">
    <nct_id>NCT00004492</nct_id>
    <title>Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">clotrimazole</intervention>
      <intervention type="Drug">hydroxyurea</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of North Carolina</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14273</other_id>
      <other_id>UNCCH-FDR001531</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <completion_date>September 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004492</url>
  </study>
  <study rank="327013">
    <nct_id>NCT00004490</nct_id>
    <title>Phase III Randomized Study of Sodium Dichloroacetate in Children With Congenital Lactic Acidosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lactic Acidosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sodium dichloroacetate</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Months</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14271</other_id>
      <other_id>UF-G-FDR001500</other_id>
      <other_id>UF-G-183-92</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004490</url>
  </study>
  <study rank="327014">
    <nct_id>NCT00004489</nct_id>
    <title>Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Osteoporosis</condition>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alendronate sodium</intervention>
      <intervention type="Drug">calcium carbonate</intervention>
      <intervention type="Drug">cholecalciferol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of North Carolina</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14270</other_id>
      <other_id>UNCCH-FDR001518</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004489</url>
  </study>
  <study rank="327015">
    <nct_id>NCT00004488</nct_id>
    <title>Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gaucher's Disease</condition>
      <condition>Osteopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alendronate sodium</intervention>
      <intervention type="Drug">calcium carbonate</intervention>
      <intervention type="Drug">cholecalciferol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Children's Hospital Medical Center, Cincinnati</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14269</other_id>
      <other_id>CHMC-C-FDR001537</other_id>
      <other_id>CHMC-C-498</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Wright State University School of Medicine, Dayton, Ohio, United States</location>
      <location>Shaare Zedek Medical Center, Jerusalem, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004488</url>
  </study>
  <study rank="327016">
    <nct_id>NCT00004487</nct_id>
    <title>Phase III Study of Chondrocyte Alginate Gel Suspension in Pediatric Patients With Vesicoureteral Reflux</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vesicoureteral Reflux</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chondrocyte-alginate gel suspension</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Curis, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14267</other_id>
      <other_id>REPRO-FDR001514</other_id>
      <other_id>REPRO-99-07</other_id>
    </other_ids>
    <start_date>May 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004487</url>
  </study>
  <study rank="327017">
    <nct_id>NCT00004486</nct_id>
    <title>Randomized Study of Fluoxetine in Children and Adolescents With Autism</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">fluoxetine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14266</other_id>
      <other_id>MTS-FDR001520</other_id>
      <other_id>MTS-GCO-96-713</other_id>
    </other_ids>
    <start_date>September 1998</start_date>
    <completion_date>December 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Albert Einstein College of Medicine, Bronx, New York, United States</location>
      <location>New York University Medical Center, New York, New York, United States</location>
      <location>Mount Sinai School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004486</url>
  </study>
  <study rank="327018">
    <nct_id>NCT00004485</nct_id>
    <title>Bone Marrow Transplantation in Treating Children With Sickle Cell Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cyclosporine</intervention>
      <intervention type="Drug">fludarabine</intervention>
      <intervention type="Drug">mycophenolate mofetil</intervention>
      <intervention type="Procedure">Bone Marrow Transplantation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Fred Hutchinson Cancer Research Center</lead_sponsor>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14243</other_id>
      <other_id>FHCRC-1373.00</other_id>
    </other_ids>
    <start_date>December 1999</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 10, 2008</last_update_posted>
    <locations>
      <location>Children's Hospital of Oakland, Oakland, California, United States</location>
      <location>Fred Hutchinson Cancer Research Center, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004485</url>
  </study>
  <study rank="327019">
    <nct_id>NCT00004483</nct_id>
    <title>NF2 Natural History Consortium</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Schwannoma, Vestibular</condition>
      <condition>Neurofibromatosis 2</condition>
      <condition>Meningioma</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>House Ear Institute</lead_sponsor>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Natural History</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14226</other_id>
      <other_id>HEI-NF2</other_id>
      <other_id>HEI-DAMD17-01-1-0710</other_id>
    </other_ids>
    <start_date>January 2002</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 29, 2005</last_update_posted>
    <locations>
      <location>House Ear Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004483</url>
  </study>
  <study rank="327020">
    <nct_id>NCT00004482</nct_id>
    <title>Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myocarditis</condition>
      <condition>Giant Cell Myocarditis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cyclosporine</intervention>
      <intervention type="Drug">methylprednisolone</intervention>
      <intervention type="Drug">Muromonab-CD3</intervention>
      <intervention type="Drug">prednisone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14209</other_id>
      <other_id>MAYOC-1479901</other_id>
      <other_id>MAYOC-1479900</other_id>
    </other_ids>
    <start_date>December 1999</start_date>
    <primary_completion_date>July 2005</primary_completion_date>
    <completion_date>July 2006</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 9, 2010</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004482</url>
  </study>
  <study rank="327021">
    <nct_id>NCT00004481</nct_id>
    <title>Genetic Study of Sitosterolemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lipid Metabolism, Inborn Errors</condition>
      <condition>Sitosterolemia</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">genetic testing</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Medical University of South Carolina</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Natural History</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR01070-0470</other_id>
      <other_id>MUSC-HR-8022</other_id>
    </other_ids>
    <start_date>November 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004481</url>
  </study>
  <study rank="327022">
    <nct_id>NCT00004480</nct_id>
    <title>Study of Botulinum Toxin in Patients With Primary Hyperhidrosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hyperhidrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">botulinum toxin type A</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14182</other_id>
      <other_id>MTS-GCO-98-913NE</other_id>
      <other_id>ALLERGAN-MTS-GCO-98-913NE</other_id>
    </other_ids>
    <start_date>July 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Mount Sinai School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004480</url>
  </study>
  <study rank="327023">
    <nct_id>NCT00004479</nct_id>
    <title>Randomized Study of Midodrine, an Alpha Adrenergic Agonist, in Patients With Neurally Mediated Syncope</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Syncope</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">midodrine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14181</other_id>
      <other_id>MTS-GCO-97-160NE</other_id>
      <other_id>ROBERTS-MTS-GCO-97-160NE</other_id>
    </other_ids>
    <start_date>March 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Mount Sinai School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004479</url>
  </study>
  <study rank="327024">
    <nct_id>NCT00004478</nct_id>
    <title>Droxidopa in Treating Patients With Neurogenic Hypotension</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Shy-Drager Syndrome</condition>
      <condition>Orthostatic Hypotension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">droxidopa</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14180</other_id>
      <other_id>MTS-GCO-98-243-3-NE</other_id>
    </other_ids>
    <start_date>March 1999</start_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <completion_date>March 2006</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 18, 2008</last_update_posted>
    <locations>
      <location>New York University School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004478</url>
  </study>
  <study rank="327025">
    <nct_id>NCT00004475</nct_id>
    <title>Genetic Linkage Study for Hereditary Pancreatitis</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pancreatitis</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO07090243</other_id>
    </other_ids>
    <start_date>December 1998</start_date>
    <primary_completion_date>December 2023</primary_completion_date>
    <completion_date>December 2023</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>July 18, 2019</last_update_posted>
    <locations>
      <location>University of Pittsburgh, Presbyterian University Hospital, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004475</url>
  </study>
  <study rank="327026">
    <nct_id>NCT00004474</nct_id>
    <title>Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Aplastic Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anti-thymocyte globulin</intervention>
      <intervention type="Drug">Cyclophosphamide</intervention>
      <intervention type="Procedure">Bone marrow transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Graft failure, graft versus host disease, and survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Roswell Park Cancer Institute</lead_sponsor>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/14004</other_id>
      <other_id>RPCI-RP-9804</other_id>
      <other_id>NCI-G98-1491</other_id>
      <other_id>IBMTR-1</other_id>
    </other_ids>
    <start_date>September 1998</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <completion_date>August 2007</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 12, 2018</last_update_posted>
    <locations>
      <location>Roswell Park Cancer Institute, Buffalo, New York, United States</location>
      <location>University of Texas - MD Anderson Cancer Center, Houston, Texas, United States</location>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
      <location>Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004474</url>
  </study>
  <study rank="327027">
    <nct_id>NCT00004471</nct_id>
    <title>Phase I Pilot Study of Gene Therapy for Cystic Fibrosis Using Cationic Liposome Mediated Gene Transfer</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">pGT-1 gene lipid complex</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13941</other_id>
      <other_id>UAB-6097</other_id>
      <other_id>UAB-F930923001</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <primary_completion_date>May 2001</primary_completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 29, 2011</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004471</url>
  </study>
  <study rank="327028">
    <nct_id>NCT00004468</nct_id>
    <title>Study of Topical Calcitriol or Oral Calcitriol in Patients With Psoriasis</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Psoriasis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">calcitriol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Boston University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13927</other_id>
      <other_id>BUSM-87-011</other_id>
      <other_id>R01DK043690</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 2, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004468</url>
  </study>
  <study rank="327029">
    <nct_id>NCT00004467</nct_id>
    <title>Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Liver Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-acetylcysteine (NAC)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall survival rate</outcome_measure>
      <outcome_measure>Survival without liver transplantation (Spontaneous Survival</outcome_measure>
      <outcome_measure>Transplant rate</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Number of organ systems showing failure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>University of Texas Southwestern Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>173</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13925 DK52827 (completed)</other_id>
      <other_id>R03DK052827</other_id>
      <other_id>UTSMC-IRB-0697-27200</other_id>
      <other_id>R01DK058369</other_id>
      <other_id>U01DK058369</other_id>
    </other_ids>
    <start_date>June 1998</start_date>
    <primary_completion_date>November 2006</primary_completion_date>
    <completion_date>November 2006</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>October 13, 2017</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham, Birmingham, Alabama, United States</location>
      <location>Mayo Clinic, Scottsdale, Arizona, United States</location>
      <location>University of California Los Angeles, Los Angeles, California, United States</location>
      <location>University of California Davis, Sacramento, California, United States</location>
      <location>University of California San Diego, San Diego, California, United States</location>
      <location>University of California San Francisco, San Francisco, California, United States</location>
      <location>Mayo Clinic, Jacksonville, Florida, United States</location>
      <location>Northwestern University Medical School, Chicago, Illinois, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>University of Michigan Health Systems, Ann Arbor, Michigan, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
      <location>University of Nebraska Medical Center, Omaha, Nebraska, United States</location>
      <location>Mount Sinai Medical Center, NY, New York, New York, United States</location>
      <location>New York Presbyterian Hospital, New York, New York, United States</location>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
      <location>Oregon Health Sciences University, Portland, Oregon, United States</location>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
      <location>Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States</location>
      <location>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States</location>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
      <location>University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States</location>
      <location>Baylor University Medical Center, Dallas, Texas, United States</location>
      <location>Virginia Commonwealth University, Richmond, Virginia, United States</location>
      <location>University of Washington Medical Center, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004467</url>
  </study>
  <study rank="327030">
    <nct_id>NCT00004466</nct_id>
    <title>Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Nephrotic Syndrome</condition>
      <condition>Hyperlipidemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atorvastatin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in plasma lipid levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Southwest Pediatric Nephrology Study Group</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13924</other_id>
      <other_id>R21DK053611</other_id>
      <other_id>PD-981-183</other_id>
      <other_id>SPNSG-97.024</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <primary_completion_date>December 1999</primary_completion_date>
    <completion_date>December 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 15, 2017</last_update_posted>
    <locations>
      <location>Medical City Dallas Hospital, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004466</url>
  </study>
  <study rank="327031">
    <nct_id>NCT00004465</nct_id>
    <title>Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemolytic Uremic Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SYNSORB Pk</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to death or serious extrarenal events</outcome_measure>
      <outcome_measure>Time to dialysis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Long Island Jewish Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>145</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13923</other_id>
      <other_id>LIJMC-96-5-186</other_id>
      <other_id>R01DK052147</other_id>
    </other_ids>
    <start_date>July 27, 1997</start_date>
    <primary_completion_date>April 14, 2001</primary_completion_date>
    <completion_date>April 14, 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 1, 2017</last_update_posted>
    <locations>
      <location>Children's Hospital of Denver, Denver, Colorado, United States</location>
      <location>Alfred I. Dupont Institute, Wilmington, Delaware, United States</location>
      <location>Emory University School of Medicine, Atlanta, Georgia, United States</location>
      <location>Medical College of Georgia Hospital and Clinics, Augusta, Georgia, United States</location>
      <location>Indiana University Cancer Center, Indianapolis, Indiana, United States</location>
      <location>Boston Floating Hospital Infants and Children, Boston, Massachusetts, United States</location>
      <location>St. Barnabas Medical Center, Livingston, New Jersey, United States</location>
      <location>Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States</location>
      <location>Children's Hospital at St. Joseph's, Paterson, New Jersey, United States</location>
      <location>Maimonides Medical Center, Brooklyn, New York, United States</location>
      <location>Children's Hospital of Buffalo, Buffalo, New York, United States</location>
      <location>North Shore University Hospital, Manhasset, New York, United States</location>
      <location>Long Island Jewish Medical Center, New Hyde Park, New York, United States</location>
      <location>Weill Medical College of Cornell University, New York, New York, United States</location>
      <location>University of Rochester Medical Center, Rochester, New York, United States</location>
      <location>State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States</location>
      <location>Jack D. Weiler Hospital of the Albert Einstein College of Medicine, The Bronx, New York, United States</location>
      <location>New York Medical College, Valhalla, New York, United States</location>
      <location>Bowman Gray School of Medicine, Winston-Salem, North Carolina, United States</location>
      <location>Ohio State University Children's Hospital, Columbus, Ohio, United States</location>
      <location>Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States</location>
      <location>Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States</location>
      <location>University of Virginia, Charlottesville, Virginia, United States</location>
      <location>Children's Hospital of the King's Daughters, Norfolk, Virginia, United States</location>
      <location>West Virginia University Hospitals, Morgantown, West Virginia, United States</location>
      <location>University of Wisconsin Children's Hospital, Madison, Wisconsin, United States</location>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004465</url>
  </study>
  <study rank="327032">
    <nct_id>NCT00004464</nct_id>
    <title>Study of High Dose Cyclophosphamide in Patients With Severe Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Aplastic Anemia</condition>
      <condition>Paroxysmal Hemoglobinuria, Nocturnal</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cyclophosphamide</intervention>
      <intervention type="Drug">filgrastim</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>69</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>J9611</other_id>
      <other_id>96-01-17-02</other_id>
      <other_id>JHOC-96011702</other_id>
      <other_id>JHOC-9611</other_id>
      <other_id>199/13895</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <primary_completion_date>March 1, 2007</primary_completion_date>
    <completion_date>November 11, 2008</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>January 18, 2019</last_update_posted>
    <locations>
      <location>Johns Hopkins Oncology Center, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004464</url>
  </study>
  <study rank="327033">
    <nct_id>NCT00004458</nct_id>
    <title>Longitudinal and Biological Study of Childhood Disintegrative Disorder</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pervasive Child Development Disorders</condition>
      <condition>Autism</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>Yale University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <max_age>9 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13682</other_id>
      <other_id>YALE-5P01HD0300830</other_id>
      <other_id>YALE-HIC-5895</other_id>
    </other_ids>
    <start_date>May 1997</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Yale Child Study Center, New Haven, Connecticut, United States</location>
      <location>University of Chicago Cancer Research Center, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004458</url>
  </study>
  <study rank="327034">
    <nct_id>NCT00004457</nct_id>
    <title>Determinants of Disease Severity in Amyotrophic Lateral Sclerosis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amyotrophic Lateral Sclerosis</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>Massachusetts General Hospital</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Defined Population</study_design>
      <study_design>Primary Purpose: Screening</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13650</other_id>
      <other_id>MGH-97-7231</other_id>
      <other_id>MGH-1K08NS01896</other_id>
    </other_ids>
    <start_date>March 1998</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004457</url>
  </study>
  <study rank="327035">
    <nct_id>NCT00004454</nct_id>
    <title>Phase I/II Study of Retroviral-Mediated Transfer of Iduronate-2-Sulfatase Gene Into Lymphocytes of Patients With Mucopolysaccharidosis II (Mild Hunter Syndrome)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mucopolysaccharidosis II</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">lymphocyte gene therapy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13577</other_id>
      <other_id>UMN-HUNTER</other_id>
      <other_id>UMN-5P01HD32652</other_id>
    </other_ids>
    <start_date>October 1996</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Minnesota Medical School, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004454</url>
  </study>
  <study rank="327036">
    <nct_id>NCT00004451</nct_id>
    <title>Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Glucose</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Mental Health (NIMH)</lead_sponsor>
      <collaborator>University of Virginia</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13548</other_id>
      <other_id>K07MH001197</other_id>
    </other_ids>
    <start_date>March 1998</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>December 1, 2005</last_update_posted>
    <locations>
      <location>University of Virginia, Charlottesville, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004451</url>
  </study>
  <study rank="327037">
    <nct_id>NCT00004450</nct_id>
    <title>Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adrenoleukodystrophy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">glyceryl trierucate</intervention>
      <intervention type="Drug">glyceryl trioleate</intervention>
      <intervention type="Drug">interferon beta</intervention>
      <intervention type="Drug">thalidomide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13532</other_id>
      <other_id>KKI-94-06-16-01</other_id>
      <other_id>KKI-FDR001052</other_id>
    </other_ids>
    <start_date>August 1998</start_date>
    <completion_date>November 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004450</url>
  </study>
  <study rank="327038">
    <nct_id>NCT00004449</nct_id>
    <title>Randomized Study of Intensive One-on-one Behavioral Treatment for Preschool Aged Children With Autism</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autistic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">intensive one-on-one behavioral treatment</intervention>
      <intervention type="Behavioral">Individualized in home parent training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Wechsler Preschool and Primary Scales of Intelligence, 3rd ed.</outcome_measure>
      <outcome_measure>Bayley Scales of Infant Development</outcome_measure>
      <outcome_measure>Merrill-Palmer Scale of Mental Tests</outcome_measure>
      <outcome_measure>Reynell Developmental Language Scales</outcome_measure>
      <outcome_measure>Vineland Adaptive Behavior Scales - Survey Edition</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute of Mental Health (NIMH)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <max_age>3 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>102</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01MH048863</other_id>
      <other_id>UCLA-HSPC-G930506611</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <primary_completion_date>September 2004</primary_completion_date>
    <completion_date>April 2006</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004449</url>
  </study>
  <study rank="327039">
    <nct_id>NCT00004448</nct_id>
    <title>Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IGA Glomerulonephritis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">omega-3 fatty acids</intervention>
      <intervention type="Drug">prednisone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Southwest Pediatric Nephrology Study Group</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>123</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13463</other_id>
      <other_id>SPNSG-5RO1DK49368</other_id>
      <other_id>SPNSG-94.052</other_id>
    </other_ids>
    <start_date>November 1997</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 10, 2008</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004448</url>
  </study>
  <study rank="327040">
    <nct_id>NCT00004446</nct_id>
    <title>Study of Fluoxetine in Patients With Depersonalization Disorder</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depersonalization Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">fluoxetine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Mental Health (NIMH)</lead_sponsor>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13456</other_id>
      <other_id>MTS-GCO-95-323</other_id>
    </other_ids>
    <start_date>April 1998</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Mount Sinai Medical Center, NY, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004446</url>
  </study>
  <study rank="327041">
    <nct_id>NCT00004445</nct_id>
    <title>Study of an Implantable Functional Neuromuscular Stimulation System for Patients With Spinal Cord Injuries</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Spinal Cord Injury</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Surgery</intervention>
      <intervention type="Device">IRS-8</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Standing Performance</outcome_measure>
      <outcome_measure>Distribution of Body Weight Through the Legs and Arms While Standing</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Case Western Reserve University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13455</other_id>
      <other_id>CWRU-FDR001244</other_id>
    </other_ids>
    <start_date>September 1996</start_date>
    <primary_completion_date>September 2009</primary_completion_date>
    <completion_date>December 31, 2016</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <results_first_posted>July 22, 2019</results_first_posted>
    <last_update_posted>August 20, 2019</last_update_posted>
    <locations>
      <location>Case Western Reserve University, Cleveland, Ohio, United States</location>
      <location>MetroHealth System, Cleveland, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004445</url>
  </study>
  <study rank="327042">
    <nct_id>NCT00004444</nct_id>
    <title>Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tuberculosis, Pulmonary</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">paromomycin</intervention>
      <intervention type="Drug">streptomycin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>University of Illinois at Chicago</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13445</other_id>
      <other_id>UIC-FDR001167</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <completion_date>January 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004444</url>
  </study>
  <study rank="327043">
    <nct_id>NCT00004443</nct_id>
    <title>Study of NTBC for Tyrosinemia I</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tyrosinemia I</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NTBC</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13443</other_id>
      <other_id>UWASH-FDR001445</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>September 2006</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Oregon Health Sciences University, Portland, Oregon, United States</location>
      <location>University of Washington School of Medicine, Seattle, Washington, United States</location>
      <location>Hopital Sainte Justine, Montreal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004443</url>
  </study>
  <study rank="327044">
    <nct_id>NCT00004442</nct_id>
    <title>Study of Bile Acids in Patients With Peroxisomal Disorders</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infantile Refsum's Disease</condition>
      <condition>Zellweger Syndrome</condition>
      <condition>Bifunctional Enzyme Deficiency</condition>
      <condition>Adrenoleukodystrophy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chenodeoxycholic acid</intervention>
      <intervention type="Drug">cholic acid</intervention>
      <intervention type="Drug">ursodiol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Cincinnati</lead_sponsor>
      <collaborator>Children's Hospital Medical Center, Cincinnati</collaborator>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>5 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13442</other_id>
      <other_id>CHMC-C-FDR000995</other_id>
    </other_ids>
    <completion_date>April 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004442</url>
  </study>
  <study rank="327045">
    <nct_id>NCT00004441</nct_id>
    <title>Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tauroursodeoxycholic acid</intervention>
      <intervention type="Drug">ursodiol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Children's Hospital Medical Center, Cincinnati</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13439</other_id>
      <other_id>CHMC-C-001439</other_id>
      <other_id>CHMC-C-96-1-8</other_id>
      <other_id>CHMC-C-FDR001439-01</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <completion_date>September 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Children's Hospital of Denver, Denver, Colorado, United States</location>
      <location>Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States</location>
      <location>University of Milan, Milan, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004441</url>
  </study>
  <study rank="327046">
    <nct_id>NCT00004440</nct_id>
    <title>Study of Ibuprofen to Preserve Lung Function in Patients With Cystic Fibrosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ibuprofen</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Case Western Reserve University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13438</other_id>
      <other_id>CWRU-FDR001185</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <completion_date>June 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004440</url>
  </study>
  <study rank="327047">
    <nct_id>NCT00004438</nct_id>
    <title>Leuprolide in Treating Adults With Hypogonadotropism</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypogonadism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">leuprolide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13402</other_id>
      <other_id>UCCH-8451</other_id>
      <other_id>UCCH-FDR001473</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>University of Chicago Children's Hospital, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004438</url>
  </study>
  <study rank="327048">
    <nct_id>NCT00004437</nct_id>
    <title>Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neurofibromatosis 2</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Multichannel Auditory Brain Stem Implant</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Cochlear</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13400</other_id>
      <other_id>CC-FDR001283</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <completion_date>October 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004437</url>
  </study>
  <study rank="327049">
    <nct_id>NCT00004436</nct_id>
    <title>Randomized Study of Hormonal Regulation of Infantile Hemangioma</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemangioma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">leuprolide</intervention>
      <intervention type="Drug">prednisone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Boston Children’s Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Month</min_age>
    <max_age>8 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13399</other_id>
      <other_id>CH-B-FDR000967</other_id>
    </other_ids>
    <start_date>July 1993</start_date>
    <completion_date>June 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004436</url>
  </study>
  <study rank="327050">
    <nct_id>NCT00004433</nct_id>
    <title>Randomized Study of Pergolide in Children With Tourette Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tourette Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">pergolide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Children's Hospital Medical Center, Cincinnati</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13395</other_id>
      <other_id>MUSC-6130</other_id>
      <other_id>MUSC-FDR001111</other_id>
    </other_ids>
    <start_date>December 1994</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004433</url>
  </study>
  <study rank="327051">
    <nct_id>NCT00004431</nct_id>
    <title>Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Trigeminal Neuralgia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">L-baclofen</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13391</other_id>
      <other_id>UPSOM-950686-9608</other_id>
      <other_id>UPSOM-FDR000914</other_id>
    </other_ids>
    <start_date>June 1998</start_date>
    <completion_date>September 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004431</url>
  </study>
  <study rank="327052">
    <nct_id>NCT00004430</nct_id>
    <title>Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corneal Neovascularization</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dihematoporphyrin derivative</intervention>
      <intervention type="Drug">prednisolone</intervention>
      <intervention type="Procedure">Laser surgery</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Medical College of Hampton Roads</lead_sponsor>
      <collaborator>Eastern Virginia Medical School</collaborator>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13380</other_id>
      <other_id>EVMS-FDR001020</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <completion_date>September 1998</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Eastern Virginia Medical School, Norfolk, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004430</url>
  </study>
  <study rank="327053">
    <nct_id>NCT00004429</nct_id>
    <title>Randomized Study of Recombinant Human Growth Hormone in Patients on Chronic Hemodialysis or Peritoneal Dialysis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Kidney Failure, Chronic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">growth hormone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Vanderbilt University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13377</other_id>
      <other_id>VUMC-FDR000943</other_id>
    </other_ids>
    <start_date>December 1999</start_date>
    <completion_date>February 2005</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004429</url>
  </study>
  <study rank="327054">
    <nct_id>NCT00004428</nct_id>
    <title>Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CPX</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>SciClone Pharmaceuticals</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13364</other_id>
      <other_id>SCICLONE-FDA-OP-97-1</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <completion_date>October 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004428</url>
  </study>
  <study rank="327055">
    <nct_id>NCT00004426</nct_id>
    <title>Leuprolide in Determining the Cause of Gonadotropin Deficiency</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypogonadism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">gonadotropin releasing hormone</intervention>
      <intervention type="Drug">leuprolide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>9 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13361</other_id>
      <other_id>UCCH-FDR001012</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <completion_date>September 1998</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 26, 2015</last_update_posted>
    <locations>
      <location>University of Chicago Children's Hospital, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004426</url>
  </study>
  <study rank="327056">
    <nct_id>NCT00004424</nct_id>
    <title>Randomized Study of Propofol Versus Fentanyl and Midazolam in Pediatric Patients Requiring Mechanical Ventilation and Sedation Therapy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiration Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">fentanyl</intervention>
      <intervention type="Drug">Midazolam</intervention>
      <intervention type="Drug">propofol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Case Western Reserve University</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13353</other_id>
      <other_id>CWRU-FDR000852</other_id>
    </other_ids>
    <start_date>July 1996</start_date>
    <completion_date>March 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004424</url>
  </study>
  <study rank="327057">
    <nct_id>NCT00004423</nct_id>
    <title>Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">-aminosalicylic acid</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13352</other_id>
      <other_id>UVTCM-FDR001021</other_id>
    </other_ids>
    <start_date>December 1995</start_date>
    <completion_date>March 1998</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004423</url>
  </study>
  <study rank="327058">
    <nct_id>NCT00004422</nct_id>
    <title>Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pertussis</condition>
      <condition>Whooping Cough</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">immune globulin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>IWK Health Centre</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>5 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>174</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13322</other_id>
      <other_id>IWK-FDR001044</other_id>
      <other_id>P9701</other_id>
    </other_ids>
    <start_date>August 1997</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004422</url>
  </study>
  <study rank="327059">
    <nct_id>NCT00004421</nct_id>
    <title>Deep Brain Stimulation in Treating Patients With Dystonia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dystonia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">implanted pulse generator</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13315</other_id>
      <other_id>MTS-FDR001452</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Mount Sinai Medical Center, NY, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004421</url>
  </study>
  <study rank="327060">
    <nct_id>NCT00004420</nct_id>
    <title>Study of Gammalinolenic Acid for Juvenile Rheumatoid Arthritis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Juvenile Rheumatoid Arthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">gamma-Linolenic acid</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>University of Massachusetts, Worcester</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13314</other_id>
      <other_id>UMASS-H-2703</other_id>
      <other_id>UMASS-FDR001067</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004420</url>
  </study>
  <study rank="327061">
    <nct_id>NCT00004419</nct_id>
    <title>Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Insulin Resistance</condition>
      <condition>Hyperglycemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">insulin-like growth factor I</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13313</other_id>
      <other_id>BIH-98-1060</other_id>
      <other_id>BIH-E-147</other_id>
      <other_id>BIH-FDR001126</other_id>
    </other_ids>
    <start_date>April 1998</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004419</url>
  </study>
  <study rank="327062">
    <nct_id>NCT00004418</nct_id>
    <title>Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adrenoleukodystrophy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">glyceryl trierucate</intervention>
      <intervention type="Drug">glyceryl trioleate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>neurological disability</outcome_measure>
      <outcome_measure>magnetic resonance imaging of the head</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Months</min_age>
    <max_age>6 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13312</other_id>
      <other_id>Nutricia-Loma Linda</other_id>
      <other_id>KKI-FDR000685</other_id>
    </other_ids>
    <start_date>April 1998</start_date>
    <primary_completion_date>November 2014</primary_completion_date>
    <completion_date>November 2014</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 18, 2014</last_update_posted>
    <locations>
      <location>Kennedy Krieger Institute, Baltimore, Maryland, United States</location>
      <location>Johns Hopkins Hospital, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004418</url>
  </study>
  <study rank="327063">
    <nct_id>NCT00004416</nct_id>
    <title>Randomized Study of Botulinum Toxin Type A for Achalasia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Esophageal Achalasia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">botulinum toxin type A</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Texas</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13308</other_id>
      <other_id>UTMB-FDR001421</other_id>
      <other_id>JHH-94122903</other_id>
      <other_id>MCMASTER-FDA</other_id>
      <other_id>UTMB-97-230</other_id>
      <other_id>UTMB-BB</other_id>
      <other_id>UTMB-GCRC-470</other_id>
    </other_ids>
    <start_date>January 1997</start_date>
    <completion_date>March 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004416</url>
  </study>
  <study rank="327064">
    <nct_id>NCT00004415</nct_id>
    <title>Study of Combined Intercostal and Diaphragm Pacing for Artificial Respiration in Quadriplegic Patients</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Quadriplegia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Medlink spinal cord electrode</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Case Western Reserve University</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13307</other_id>
      <other_id>CWRU-09169-M-91</other_id>
      <other_id>CWRU-FDR000403</other_id>
    </other_ids>
    <start_date>May 1991</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>April 7, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004415</url>
  </study>
  <study rank="327065">
    <nct_id>NCT00004414</nct_id>
    <title>Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cholestasis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sincalide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>30 Days</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>252</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13306</other_id>
      <other_id>UMMS-FDR001449</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <completion_date>June 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Johns Hopkins Oncology Center, Baltimore, Maryland, United States</location>
      <location>University of Michigan Medical School, Ann Arbor, Michigan, United States</location>
      <location>University of Rochester Medical Center, Rochester, New York, United States</location>
      <location>Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States</location>
      <location>Rhode Island Hospital, Providence, Rhode Island, United States</location>
      <location>Baylor University Medical Center, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004414</url>
  </study>
  <study rank="327066">
    <nct_id>NCT00004412</nct_id>
    <title>Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Skin Ulcers</condition>
      <condition>Sickle Cell Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Arginine Butyrate</intervention>
      <intervention type="Other">Standard local care dressing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Healing Defined as a Decrease in Ulcer Area by at Least 25% of the Initial Area</outcome_measure>
      <outcome_measure>% Ulcers Which Completely Healed in Each Group, After 3 Months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Susan P. Perrine</lead_sponsor>
      <collaborator>Boston Medical Center</collaborator>
      <collaborator>University of Illinois at Chicago</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>University of Tennessee Health Science Center</collaborator>
      <collaborator>Schneider Children's Medical Center, Israel</collaborator>
      <collaborator>Boston University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13302</other_id>
      <other_id>BUSM-FDR001376</other_id>
      <other_id>IND 36,957</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <primary_completion_date>December 2002</primary_completion_date>
    <completion_date>February 2005</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <results_first_posted>March 31, 2015</results_first_posted>
    <last_update_posted>March 31, 2015</last_update_posted>
    <locations>
      <location>University of Illinois College of Medicine, Chicago, Illinois, United States</location>
      <location>Boston University School of Medicine, Boston, Massachusetts, United States</location>
      <location>Mount Sinai School of Medicine, New York, New York, United States</location>
      <location>University of Tennessee, Memphis Cancer Center, Memphis, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004412</url>
  </study>
  <study rank="327067">
    <nct_id>NCT00004410</nct_id>
    <title>Randomized Study of Tauroursodeoxycholic Acid in Prophylactic Therapy of Total Parenteral Nutrition Associated Cholestasis in Infants</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cholestasis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tauroursodeoxycholic acid</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Children's Hospital Medical Center, Cincinnati</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>20 Days</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13299</other_id>
      <other_id>CHMC-C-95-9-9</other_id>
      <other_id>CHMC-C-CRC-473</other_id>
      <other_id>CHMC-C-FDR001277</other_id>
    </other_ids>
    <start_date>June 1998</start_date>
    <completion_date>March 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Children's Hospitals and Clinics - Minneapolis, Minneapolis, Minnesota, United States</location>
      <location>University of Mississippi Medical Center, Jackson, Mississippi, United States</location>
      <location>Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004410</url>
  </study>
  <study rank="327068">
    <nct_id>NCT00004409</nct_id>
    <title>Phase II Randomized Study of Collagenase in Patients With Residual Type Dupuytren's Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dupuytren's Contracture</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">collagenase</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>State University of New York</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13297</other_id>
      <other_id>SUNY-SB-FDR001373</other_id>
      <other_id>DUPY-101</other_id>
      <other_id>DUPY-202</other_id>
      <other_id>SUNY-SB-431-1007A</other_id>
      <other_id>SUNY-SB-431-8804B</other_id>
      <other_id>SUNY-SB-431-X2020</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <completion_date>April 2004</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Stanford University Hospital, Palo Alto, California, United States</location>
      <location>State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004409</url>
  </study>
  <study rank="327069">
    <nct_id>NCT00004408</nct_id>
    <title>Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">poloxamer 188</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Mast Therapeutics, Inc.</lead_sponsor>
      <collaborator>CytRx</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13296</other_id>
      <other_id>CYTRX-C97-1248</other_id>
      <other_id>CYTRX-FDR001433</other_id>
    </other_ids>
    <start_date>November 1997</start_date>
    <completion_date>November 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 6, 2012</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004408</url>
  </study>
  <study rank="327070">
    <nct_id>NCT00004407</nct_id>
    <title>Randomized Study of Intravenous Immunoglobulin (IVIg) in Patients With Subacute Proximal Diabetic Neuropathy</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Neuropathies</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">immune globulin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13294</other_id>
      <other_id>MAYOC-91596</other_id>
      <other_id>MAYOC-FDR001358</other_id>
    </other_ids>
    <start_date>February 1998</start_date>
    <completion_date>March 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004407</url>
  </study>
  <study rank="327071">
    <nct_id>NCT00004406</nct_id>
    <title>Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Osteoporosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">human parathyroid hormone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>29 Years</min_age>
    <max_age>67 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13293</other_id>
      <other_id>CPS-CU-FDR001024</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <completion_date>July 2004</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Columbia University College of Physicians and Surgeons, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004406</url>
  </study>
  <study rank="327072">
    <nct_id>NCT00004404</nct_id>
    <title>Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">clotrimazole</intervention>
      <intervention type="Drug">hydroxyurea</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Boston Children’s Hospital</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13288</other_id>
      <other_id>CH-B-97-052</other_id>
      <other_id>CH-B-FDR001022</other_id>
    </other_ids>
    <start_date>April 1997</start_date>
    <completion_date>September 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
      <location>Children's Hospital - Boston, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004404</url>
  </study>
  <study rank="327073">
    <nct_id>NCT00004403</nct_id>
    <title>Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epilepsy</condition>
      <condition>Cysticercosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">albendazole</intervention>
      <intervention type="Drug">dexamethasone</intervention>
      <intervention type="Drug">phenytoin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13286</other_id>
      <other_id>JHUSHPH-FDR001107</other_id>
    </other_ids>
    <start_date>May 2000</start_date>
    <completion_date>March 2002</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004403</url>
  </study>
  <study rank="327074">
    <nct_id>NCT00004402</nct_id>
    <title>Phase III Randomized Study of Interferon Gamma in Children With Severe, Congenital Osteopetrosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Osteopetrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">calcitriol</intervention>
      <intervention type="Drug">interferon gamma</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>Medical University of South Carolina</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>10 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13284</other_id>
      <other_id>MUSC-FDR000768</other_id>
    </other_ids>
    <start_date>November 1999</start_date>
    <completion_date>June 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004402</url>
  </study>
  <study rank="327075">
    <nct_id>NCT00004401</nct_id>
    <title>Study of Human Botulism Immunoglobulin in Infants With Botulism</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infant Botulism</condition>
      <condition>Botulism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">botulism immune globulin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>California Department of Health Services</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Year</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13253</other_id>
      <other_id>CDHS-FDU000476</other_id>
    </other_ids>
    <start_date>January 1998</start_date>
    <completion_date>June 1998</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>California Department of Health Services, Berkeley, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004401</url>
  </study>
  <study rank="327076">
    <nct_id>NCT00004400</nct_id>
    <title>Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Cachexia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">testosterone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Charles Drew University of Medicine and Science</lead_sponsor>
      <collaborator>FDA Office of Orphan Products Development</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13251</other_id>
      <other_id>CDUMS-FDR001397</other_id>
    </other_ids>
    <start_date>April 1997</start_date>
    <completion_date>September 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations>
      <location>Charles R. Drew University of Medicine and Science, Los Angeles, California, United States</location>
      <location>Los Angeles County Harbor-UCLA Medical Center, Torrance, California, United States</location>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004400</url>
  </study>
  <study rank="327077">
    <nct_id>NCT00004399</nct_id>
    <title>Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pre-eclampsia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">magnesium sulfate</intervention>
      <intervention type="Drug">nimodipine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>FDA Office of Orphan Products Development</lead_sponsor>
      <collaborator>University of Utah</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13249</other_id>
      <other_id>UU-FDR001061</other_id>
      <other_id>BCM-FDR001061</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <completion_date>August 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 25, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004399</url>
  </study>
  <study rank="327078">
    <nct_id>NCT00004398</nct_id>
    <title>Phase I Study of Heme Arginate With or Without Tin Mesoporphyrin in Patients With Acute Attacks of Porphyria</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Porphyria</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">heme arginate</intervention>
      <intervention type="Drug">tin mesoporphyrin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13191</other_id>
      <other_id>UTMB-97-118</other_id>
      <other_id>UTMB-FDR001459</other_id>
    </other_ids>
    <start_date>January 1998</start_date>
    <completion_date>May 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004398</url>
  </study>
  <study rank="327079">
    <nct_id>NCT00004397</nct_id>
    <title>Phase I Study of Tin Mesoporphyrin in Patients on Long Term Heme Therapy for Prevention of Acute Attacks of Porphyria</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Porphyria</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">heme arginate</intervention>
      <intervention type="Drug">tin mesoporphyrin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13187</other_id>
      <other_id>UTMB-97-117</other_id>
      <other_id>UTMB-FDR001459</other_id>
    </other_ids>
    <start_date>January 1998</start_date>
    <completion_date>May 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004397</url>
  </study>
  <study rank="327080">
    <nct_id>NCT00004396</nct_id>
    <title>Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acute Porphyrias</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Porphyria</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">heme arginate</intervention>
      <intervention type="Drug">tin mesoporphyrin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/13185</other_id>
      <other_id>UTMB-96-476</other_id>
      <other_id>UTMB-96-318</other_id>
      <other_id>UTMB-FDR000710</other_id>
      <other_id>UTMB-FDR001459</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Rockefeller University Hospital, New York, New York, United States</location>
      <location>University of Texas Medical Branch, Galveston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004396</url>
  </study>
  <study rank="327081">
    <nct_id>NCT00004393</nct_id>
    <title>Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tourette Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">risperidone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Yale University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12217</other_id>
      <other_id>YALESM-7764</other_id>
    </other_ids>
    <start_date>July 1997</start_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004393</url>
  </study>
  <study rank="327082">
    <nct_id>NCT00004392</nct_id>
    <title>Incidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for Sudden Infant Death Syndrome (SIDS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sudden Infant Death Syndrome</condition>
      <condition>Apnea</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>Yale University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Year</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12190</other_id>
      <other_id>YALESM-CHIME-HD9102</other_id>
    </other_ids>
    <start_date>May 1994</start_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004392</url>
  </study>
  <study rank="327083">
    <nct_id>NCT00004390</nct_id>
    <title>Phase III Randomized Controlled Study of Morphine and Nortriptyline in the Management of Postherpetic Neuralgia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pain</condition>
      <condition>Herpes Zoster</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">desipramine</intervention>
      <intervention type="Drug">methadone</intervention>
      <intervention type="Drug">morphine</intervention>
      <intervention type="Drug">nortriptyline</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>Johns Hopkins University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12133</other_id>
      <other_id>JHUSM-93010802</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004390</url>
  </study>
  <study rank="327084">
    <nct_id>NCT00004387</nct_id>
    <title>Phase II Double Blind Controlled Trial of Nigral Grafting in Patients With Parkinson's Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">fetal nigral transplantation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Neurological Disorders and Stroke (NINDS)</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12102</other_id>
      <other_id>MTS-94339</other_id>
      <other_id>MTS-GCO-94-339</other_id>
    </other_ids>
    <start_date>January 1996</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004387</url>
  </study>
  <study rank="327085">
    <nct_id>NCT00004386</nct_id>
    <title>Phase I Pilot Study of Liver-Directed Gene Therapy for Partial Ornithine Transcarbamylase Deficiency</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ornithine Transcarbamylase Deficiency Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">recombinant adenovirus containing the ornithine transcarbamylase gene</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>Children's Research Institute</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12054</other_id>
      <other_id>CSH-3660</other_id>
    </other_ids>
    <start_date>October 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004386</url>
  </study>
  <study rank="327086">
    <nct_id>NCT00004382</nct_id>
    <title>Phase II Study of Tin Mesoporphyrin vs Phototherapy for Hyperbilirubinemia in Premature Newborns</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hyperbilirubinemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tin mesoporphyrin</intervention>
      <intervention type="Procedure">Phototherapy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>Rockefeller University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>24 Hours</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12022</other_id>
      <other_id>RUH-0330795B</other_id>
    </other_ids>
    <start_date>December 1999</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 9, 2008</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004382</url>
  </study>
  <study rank="327087">
    <nct_id>NCT00004381</nct_id>
    <title>Phase II Randomized Study of Tin Mesoporphyrin for Neonatal Hyperbilirubinemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glucosephosphate Dehydrogenase Deficiency</condition>
      <condition>Hyperbilirubinemia</condition>
      <condition>Hemolytic Disease of Newborn</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tin mesoporphyrin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>Rockefeller University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>24 Hours</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12021</other_id>
      <other_id>RUH-0330795A</other_id>
    </other_ids>
    <start_date>December 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>New England Medical Center Hospital, Boston, Massachusetts, United States</location>
      <location>Rockefeller University Hospital, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004381</url>
  </study>
  <study rank="327088">
    <nct_id>NCT00004380</nct_id>
    <title>Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Systemic Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">relaxin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</collaborator>
      <collaborator>Stanford University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/12015</other_id>
      <other_id>SUMC-37488</other_id>
    </other_ids>
    <start_date>December 1991</start_date>
    <completion_date>December 1997</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004380</url>
  </study>
  <study rank="327089">
    <nct_id>NCT00004378</nct_id>
    <title>Stem Cell Transplantation (SCT) for Genetic Diseases</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thrombocytopenia</condition>
      <condition>Metachromatic Leukodystrophy</condition>
      <condition>Fanconi's Anemia</condition>
      <condition>Thalassemia Major</condition>
      <condition>Pure Red-Cell Aplasia</condition>
      <condition>Inborn Errors of Metabolism</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Stem Cell Transplantation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11981</other_id>
      <other_id>UCLA-92010034</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of California Los Angeles Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004378</url>
  </study>
  <study rank="327090">
    <nct_id>NCT00004376</nct_id>
    <title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tourette Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">guanfacine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Yale University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11979</other_id>
      <other_id>YALESM-7588</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <completion_date>June 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004376</url>
  </study>
  <study rank="327091">
    <nct_id>NCT00004375</nct_id>
    <title>Ultraviolet Light Therapy for Systemic Lupus Erythematosus</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Systemic Lupus Erythematosus</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">ultraviolet A-1 light treatment</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Louisiana State University Health Sciences Center in New Orleans</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR05096-0002</other_id>
      <other_id>LSUMC-1765</other_id>
      <other_id>LSUMC-910067</other_id>
    </other_ids>
    <start_date>September 1991</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>General Clinical Research Center and Charity Hospital (University of Louisiana), New Orleans, Louisiana, United States</location>
      <location>Alton Ochsner Medical Foundation Hospital, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004375</url>
  </study>
  <study rank="327092">
    <nct_id>NCT00004374</nct_id>
    <title>Study of Systemic Amyloidosis Presentation and Prognosis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amyloidosis</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Indiana University School of Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00750-0062</other_id>
      <other_id>IUSM-831215</other_id>
    </other_ids>
    <start_date>January 1979</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Indiana University Cancer Center, Indianapolis, Indiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004374</url>
  </study>
  <study rank="327093">
    <nct_id>NCT00004373</nct_id>
    <title>Phase II Double-Blind, Placebo-Controlled Study of the Reinforcing Effects of Alprazolam in Patients With Anxiety</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anxiety Disorder</condition>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">alprazolam</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11960</other_id>
      <other_id>UTHSC-92120</other_id>
    </other_ids>
    <start_date>March 1997</start_date>
    <completion_date>March 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004373</url>
  </study>
  <study rank="327094">
    <nct_id>NCT00004368</nct_id>
    <title>Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cirrhosis</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">colchicine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Children's Hospital Colorado</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11947</other_id>
      <other_id>CHD-1089</other_id>
    </other_ids>
    <start_date>May 1990</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004368</url>
  </study>
  <study rank="327095">
    <nct_id>NCT00004367</nct_id>
    <title>Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without Agoraphobia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anxiety Disorder</condition>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Clinical vestibular tests</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11945</other_id>
      <other_id>UPITTS-9504279605</other_id>
    </other_ids>
    <start_date>May 2000</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Pittsburgh, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004367</url>
  </study>
  <study rank="327096">
    <nct_id>NCT00004366</nct_id>
    <title>Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vestibular Diseases</condition>
      <condition>Agoraphobia</condition>
      <condition>Panic Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Physical therapy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Educational/Counseling/Training</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11944</other_id>
      <other_id>UPITTS-11760S-950866</other_id>
      <other_id>11760S-950866</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <completion_date>May 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004366</url>
  </study>
  <study rank="327097">
    <nct_id>NCT00004365</nct_id>
    <title>Study of Pituitary Size and Function in Familial Dwarfism of Sindh</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Growth Hormone Deficiency</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Northwestern University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11940</other_id>
      <other_id>NU-571</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <completion_date>February 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004365</url>
  </study>
  <study rank="327098">
    <nct_id>NCT00004364</nct_id>
    <title>Study of Novel Types of Familial Diabetes Insipidus</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Insipidus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">desmopressin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Northwestern University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11939</other_id>
      <other_id>NU-570</other_id>
    </other_ids>
    <start_date>December 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>February 22, 2006</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004364</url>
  </study>
  <study rank="327099">
    <nct_id>NCT00004363</nct_id>
    <title>Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Insipidus</condition>
      <condition>Diabetes Insipidus, Neurohypophyseal</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chlorpropamide</intervention>
      <intervention type="Drug">desmopressin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Northwestern University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00048-0568</other_id>
      <other_id>NU-568</other_id>
    </other_ids>
    <start_date>December 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Northwestern University Medical School, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004363</url>
  </study>
  <study rank="327100">
    <nct_id>NCT00004361</nct_id>
    <title>Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypoparathyroidism</condition>
      <condition>Tetralogy of Fallot</condition>
      <condition>Pulmonary Valve Stenosis</condition>
      <condition>Conotruncal Cardiac Defects</condition>
      <condition>Heart Defects, Congenital</condition>
      <condition>Pulmonary Atresia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">calcium gluconate</intervention>
      <intervention type="Drug">sodium citrate</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Ann &amp; Robert H Lurie Children's Hospital of Chicago</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11936</other_id>
      <other_id>NU-553</other_id>
    </other_ids>
    <start_date>July 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004361</url>
  </study>
  <study rank="327101">
    <nct_id>NCT00004360</nct_id>
    <title>Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Insipidus, Nephrogenic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chlorothiazide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Northwestern University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11929</other_id>
      <other_id>NU-513</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004360</url>
  </study>
  <study rank="327102">
    <nct_id>NCT00004359</nct_id>
    <title>Phase II Pilot Study of Extracorporeal Phototherapy for Epidermolysis Bullosa Acquisita</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epidermolysis Bullosa Acquisita</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">methoxsalen</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Northwestern University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11928</other_id>
      <other_id>NU-511</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004359</url>
  </study>
  <study rank="327103">
    <nct_id>NCT00004358</nct_id>
    <title>Phase II Study of Calcitonin for Tumoral Calcinosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Calcinosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">calcitonin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Ann &amp; Robert H Lurie Children's Hospital of Chicago</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11925</other_id>
      <other_id>NU-477</other_id>
    </other_ids>
    <start_date>November 1992</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Children's Memorial Hospital, Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004358</url>
  </study>
  <study rank="327104">
    <nct_id>NCT00004357</nct_id>
    <title>Absorption of Corticosteroids in Children With Juvenile Dermatomyositis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vasculitis, Hypersensitivity</condition>
      <condition>Connective Tissue Diseases</condition>
      <condition>Dermatomyositis</condition>
      <condition>Vasculitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">Prednisolone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
      <collaborator>Ann &amp; Robert H Lurie Children's Hospital of Chicago</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>21 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11924</other_id>
      <other_id>NU-465</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <primary_completion_date>December 2005</primary_completion_date>
    <completion_date>February 2008</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>July 22, 2011</last_update_posted>
    <locations>
      <location>Children's Memorial Hospital, Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004357</url>
  </study>
  <study rank="327105">
    <nct_id>NCT00004356</nct_id>
    <title>Study of Homocysteine Metabolism in Homocystinuria</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Homocystinuria</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11920</other_id>
      <other_id>UCSD-1033</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <completion_date>October 2000</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004356</url>
  </study>
  <study rank="327106">
    <nct_id>NCT00004354</nct_id>
    <title>Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hyperaldosteronism</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Brigham and Women's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11917</other_id>
      <other_id>BWH-91328603</other_id>
    </other_ids>
    <start_date>June 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004354</url>
  </study>
  <study rank="327107">
    <nct_id>NCT00004353</nct_id>
    <title>Study of the Metabolism of Pyruvate and Related Problems in Patients With Lactic Acidemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mitochondrial Myopathy</condition>
      <condition>MELAS Syndrome</condition>
      <condition>Lactic Acidosis</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, San Diego</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NCRR-M01RR00827-0071</other_id>
      <other_id>UCSD-071</other_id>
    </other_ids>
    <start_date>December 1978</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>July 10, 2008</last_update_posted>
    <locations>
      <location>University of California San Diego Medical Center, San Diego, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004353</url>
  </study>
  <study rank="327108">
    <nct_id>NCT00004351</nct_id>
    <title>Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Williams Syndrome</condition>
      <condition>Angelman Syndrome</condition>
      <condition>Prader-Willi Syndrome</condition>
      <condition>Shprintzen Syndrome</condition>
      <condition>Smith-Magenis Syndrome</condition>
      <condition>DiGeorge Syndrome</condition>
      <condition>Chromosome Abnormalities</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>Baylor College of Medicine</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11914</other_id>
      <other_id>BCM-H4299</other_id>
    </other_ids>
    <start_date>September 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004351</url>
  </study>
  <study rank="327109">
    <nct_id>NCT00004350</nct_id>
    <title>Evaluation of Fanconi Syndrome and Cystinosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystinosis</condition>
      <condition>Fanconi Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11911</other_id>
      <other_id>UCSD-012</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004350</url>
  </study>
  <study rank="327110">
    <nct_id>NCT00004348</nct_id>
    <title>Study of Protein Translocation in Patients With Beta-Oxidation Disorders</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Beta-Oxidation Disorder</condition>
      <condition>Peroxisomal Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Washington University School of Medicine</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11907</other_id>
      <other_id>WUSM-880075R</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004348</url>
  </study>
  <study rank="327111">
    <nct_id>NCT00004347</nct_id>
    <title>Phase II Study of Dietary Cholesterol for Smith-Lemli-Opitz Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Smith-Lemli-Opitz Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">diet</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Oregon Health and Science University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00334-0068</other_id>
      <other_id>OHSU-4019</other_id>
    </other_ids>
    <start_date>November 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Oregon Health and Science University, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004347</url>
  </study>
  <study rank="327112">
    <nct_id>NCT00004346</nct_id>
    <title>Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cerebrotendinous Xanthomatosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chenodeoxycholic acid</intervention>
      <intervention type="Drug">lovastatin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Oregon Health and Science University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00334-0067</other_id>
      <other_id>OHSU-4008</other_id>
    </other_ids>
    <start_date>January 1996</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Oregon Health and Science University, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004346</url>
  </study>
  <study rank="327113">
    <nct_id>NCT00004345</nct_id>
    <title>Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Usher Syndrome</condition>
      <condition>Retinitis Pigmentosa</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Oregon Health and Science University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11904</other_id>
      <other_id>OHSU-2650</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Oregon Health Sciences University, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004345</url>
  </study>
  <study rank="327114">
    <nct_id>NCT00004344</nct_id>
    <title>Purification of Testis-Stimulating Factor in Precocious Puberty</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Precocious Puberty</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">leuprolide</intervention>
      <intervention type="Drug">testosterone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Oregon Health and Science University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11903</other_id>
      <other_id>OHSU-3328</other_id>
    </other_ids>
    <start_date>January 1997</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004344</url>
  </study>
  <study rank="327115">
    <nct_id>NCT00004343</nct_id>
    <title>Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cushing's Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Oregon Health and Science University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00334-0028</other_id>
      <other_id>OHSU-3324</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Oregon Health Sciences University, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004343</url>
  </study>
  <study rank="327116">
    <nct_id>NCT00004342</nct_id>
    <title>International Registry for Severe Chronic Neutropenia</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neutropenia</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Washington</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Natural History</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11901</other_id>
      <other_id>UW-730</other_id>
    </other_ids>
    <start_date>June 1994</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Women's Hospital, Ann Arbor, Michigan, United States</location>
      <location>St. Barnabas Medical Center, Livingston, New Jersey, United States</location>
      <location>University of Washington School of Medicine, Seattle, Washington, United States</location>
      <location>Central Highlands Oncology Program, Ballarat, Victoria, Australia</location>
      <location>CancerCare Manitoba, Winnipeg, Manitoba, Canada</location>
      <location>Hospital for Sick Children, Toronto, Ontario, Canada</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Istituto Giannina Gaslini, Genova, Italy</location>
      <location>St. James's Hospital, Leeds, England, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004342</url>
  </study>
  <study rank="327117">
    <nct_id>NCT00004341</nct_id>
    <title>Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>X-Linked Agammaglobulinemia</condition>
      <condition>X-Linked Hyper IgM Syndrome</condition>
      <condition>Wiskott-Aldrich Syndrome</condition>
      <condition>Leukocyte Adhesion Deficiency Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>University of Washington</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11900</other_id>
      <other_id>UW-533</other_id>
    </other_ids>
    <start_date>July 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Washington School of Medicine, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004341</url>
  </study>
  <study rank="327118">
    <nct_id>NCT00004340</nct_id>
    <title>Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Renal Osteodystrophy</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">calcitriol</intervention>
      <intervention type="Drug">growth hormone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>109</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11899</other_id>
      <other_id>UCLA-612</other_id>
    </other_ids>
    <start_date>June 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of California Los Angeles School of Medicine, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004340</url>
  </study>
  <study rank="327119">
    <nct_id>NCT00004339</nct_id>
    <title>Study of Tetrathiomolybdate in Patients With Wilson Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Wilson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tetrathiomolybdate</intervention>
      <intervention type="Drug">trientine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00042-1850</other_id>
      <other_id>UMMC-801</other_id>
      <other_id>UMICH-FDU000505</other_id>
    </other_ids>
    <start_date>January 1994</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>May 9, 2006</last_update_posted>
    <locations>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004339</url>
  </study>
  <study rank="327120">
    <nct_id>NCT00004338</nct_id>
    <title>Study of Zinc for Wilson Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Wilson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">zinc acetate</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11897</other_id>
      <other_id>UMMC-310</other_id>
    </other_ids>
    <start_date>October 1993</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Michigan Health Systems, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004338</url>
  </study>
  <study rank="327121">
    <nct_id>NCT00004336</nct_id>
    <title>Pilot Study of Familial Nonsyndromal Mondini Dysplasia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mondini Dysplasia</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11895</other_id>
      <other_id>UMMC-1402</other_id>
    </other_ids>
    <start_date>October 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Michigan Health Systems, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004336</url>
  </study>
  <study rank="327122">
    <nct_id>NCT00004335</nct_id>
    <title>Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypogonadism</condition>
      <condition>Precocious Puberty</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</collaborator>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11894</other_id>
      <other_id>UMMC-271</other_id>
    </other_ids>
    <start_date>April 1993</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Michigan Health Systems, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004335</url>
  </study>
  <study rank="327123">
    <nct_id>NCT00004334</nct_id>
    <title>Study of Depression, Peptides, and Steroids in Cushing's Syndrome</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cushing's Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00042-1781</other_id>
      <other_id>UMMC-701</other_id>
    </other_ids>
    <start_date>July 1994</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Michigan Health Systems, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004334</url>
  </study>
  <study rank="327124">
    <nct_id>NCT00004333</nct_id>
    <title>Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tyrosinemia, Type I</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NTBC</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11892</other_id>
      <other_id>UMMC-1319</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004333</url>
  </study>
  <study rank="327125">
    <nct_id>NCT00004332</nct_id>
    <title>Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acromegaly</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>148</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11890</other_id>
      <other_id>UMMC-1016</other_id>
    </other_ids>
    <start_date>May 1993</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004332</url>
  </study>
  <study rank="327126">
    <nct_id>NCT00004331</nct_id>
    <title>Studies in Porphyria I: Characterization of Enzyme Defects</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Porphyria</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11888</other_id>
      <other_id>UTMB-399</other_id>
    </other_ids>
    <start_date>November 1992</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Texas Medical Branch, Galveston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004331</url>
  </study>
  <study rank="327127">
    <nct_id>NCT00004330</nct_id>
    <title>Studies in Porphyria IV: Gonadotropin-Releasing Hormone (GnRH) Analogues for Prevention of Cyclic Attacks</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Porphyria</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">luteinizing hormone-releasing factor</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11885</other_id>
      <other_id>UTMB-445</other_id>
      <other_id>UTMB-312</other_id>
    </other_ids>
    <start_date>March 1987</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Texas Medical Branch, Galveston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004330</url>
  </study>
  <study rank="327128">
    <nct_id>NCT00004329</nct_id>
    <title>Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lipodystrophy</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11884</other_id>
      <other_id>UTMB-437</other_id>
    </other_ids>
    <start_date>November 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Texas Medical Branch, Galveston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004329</url>
  </study>
  <study rank="327129">
    <nct_id>NCT00004328</nct_id>
    <title>Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pseudohypoaldosteronism</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">enalapril</intervention>
      <intervention type="Drug">polystyrene sulfonate</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11883</other_id>
      <other_id>UTMB-403</other_id>
    </other_ids>
    <start_date>December 1992</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004328</url>
  </study>
  <study rank="327130">
    <nct_id>NCT00004327</nct_id>
    <title>Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory Hereditary Hemorrhagic Telangiectasia and Senile Ectasia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hereditary Hemorrhagic Telangiectasia</condition>
      <condition>Ectasia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">octreotide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Yale University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11875</other_id>
      <other_id>YALESM-7893</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004327</url>
  </study>
  <study rank="327131">
    <nct_id>NCT00004326</nct_id>
    <title>Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cushing's Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11872</other_id>
      <other_id>UMMC-1043</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Michigan Health Systems, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004326</url>
  </study>
  <study rank="327132">
    <nct_id>NCT00004325</nct_id>
    <title>Study of the Neurobiology of Tourette Syndrome and Related Disorders</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tourette Syndrome</condition>
      <condition>Obsessive Compulsive Disorder</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11866</other_id>
      <other_id>YALESM-4601</other_id>
    </other_ids>
    <start_date>December 1988</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Yale University School of Medicine, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004325</url>
  </study>
  <study rank="327133">
    <nct_id>NCT00004324</nct_id>
    <title>Developmental Phenomenology of Obsessive Compulsive Disorder and Tourette Syndrome in Children and Adolescents</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tourette Syndrome</condition>
      <condition>Obsessive Compulsive Disorder</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR06022-5099</other_id>
      <other_id>YALESM-5099</other_id>
    </other_ids>
    <start_date>December 1989</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Yale University School of Medicine, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004324</url>
  </study>
  <study rank="327134">
    <nct_id>NCT00004323</nct_id>
    <title>Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Aplastic Anemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">anti-thymocyte globulin</intervention>
      <intervention type="Drug">cyclophosphamide</intervention>
      <intervention type="Drug">cyclosporine</intervention>
      <intervention type="Drug">mesna</intervention>
      <intervention type="Drug">methotrexate</intervention>
      <intervention type="Drug">methylprednisolone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11863</other_id>
      <other_id>UCLA-94020602</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Center for Health Sciences, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004323</url>
  </study>
  <study rank="327135">
    <nct_id>NCT00004317</nct_id>
    <title>Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Toxoplasmosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Leucovorin calcium</intervention>
      <intervention type="Drug">Pyrimethamine</intervention>
      <intervention type="Drug">Spiramycin</intervention>
      <intervention type="Drug">Sulfadiazine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Persistent motor abnormality</outcome_measure>
      <outcome_measure>Vision</outcome_measure>
      <outcome_measure>Hearing</outcome_measure>
      <outcome_measure>New chorioretinal lesion</outcome_measure>
      <outcome_measure>IQ less than 70</outcome_measure>
      <outcome_measure>Decrease in IQ of greater than or equal to 15 points</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>University of Chicago</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11837</other_id>
      <other_id>UCCRC-08796</other_id>
      <other_id>MRH-850410</other_id>
      <other_id>UCRCC-08796</other_id>
    </other_ids>
    <start_date>July 2000</start_date>
    <primary_completion_date>December 2030</primary_completion_date>
    <completion_date>December 2030</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>May 14, 2009</last_update_posted>
    <locations>
      <location>University of Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004317</url>
  </study>
  <study rank="327136">
    <nct_id>NCT00004316</nct_id>
    <title>Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Interstitial Cystitis</condition>
      <condition>Vulvar Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">capsaicin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>139</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11835</other_id>
      <other_id>UPMC-950666</other_id>
    </other_ids>
    <start_date>June 1995</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 9, 2008</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004316</url>
  </study>
  <study rank="327137">
    <nct_id>NCT00004315</nct_id>
    <title>Phase II Pilot Study to Compare the Bioavailability of Buffered, Enteric-Coated Ursodiol With Unmodified Ursodiol for Chronic Cholestatic Liver Disease and Cystic Fibrosis-Associated Liver Disease</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
      <condition>Gastrointestinal Diseases</condition>
      <condition>Cholestasis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ursodiol</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Children's Hospital Medical Center, Cincinnati</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11827</other_id>
      <other_id>UCMC-CHMC-915717</other_id>
    </other_ids>
    <start_date>November 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004315</url>
  </study>
  <study rank="327138">
    <nct_id>NCT00004314</nct_id>
    <title>Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lesch-Nyhan Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">aminomidazole carboxamide riboside</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11823</other_id>
      <other_id>UCSD-733</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004314</url>
  </study>
  <study rank="327139">
    <nct_id>NCT00004313</nct_id>
    <title>Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone Replacement for Primary Adrenal Insufficiency</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Addison's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">dehydroepiandrosterone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of California, Los Angeles</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11822</other_id>
      <other_id>UCSD-1062</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004313</url>
  </study>
  <study rank="327140">
    <nct_id>NCT00004312</nct_id>
    <title>Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystinosis</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</collaborator>
      <collaborator>University of California, San Diego</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00827-1196</other_id>
      <other_id>UCSD-970026</other_id>
      <other_id>UCSD-950338</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of California San Diego School of Medicine, La Jolla, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004312</url>
  </study>
  <study rank="327141">
    <nct_id>NCT00004311</nct_id>
    <title>Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acanthosis Nigricans</condition>
      <condition>Polycystic Ovary Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">leuprolide acetate</intervention>
      <intervention type="Drug">spironolactone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Baylor College of Medicine</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11816</other_id>
      <other_id>BCM-467</other_id>
    </other_ids>
    <start_date>July 1989</start_date>
    <completion_date>January 1996</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004311</url>
  </study>
  <study rank="327142">
    <nct_id>NCT00004310</nct_id>
    <title>Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obsessive-Compulsive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clomipramine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Stanford University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>76</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11812</other_id>
      <other_id>SUMC-36784</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Stanford University Medical Center, Stanford, California, United States</location>
      <location>University of Cincinnati Medical Center, Cincinnati, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004310</url>
  </study>
  <study rank="327143">
    <nct_id>NCT00004307</nct_id>
    <title>Study of Treatment and Metabolism in Patients With Urea Cycle Disorders</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amino Acid Metabolism, Inborn Errors</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Protein and calorie controlled diet</intervention>
      <intervention type="Genetic">Ornithine transcarbamylase vector</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Baylor College of Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NCRR-M01RR00188-0606</other_id>
      <other_id>BCM-H4379</other_id>
    </other_ids>
    <start_date>December 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004307</url>
  </study>
  <study rank="327144">
    <nct_id>NCT00004306</nct_id>
    <title>Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hereditary Ataxia</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Office of Rare Diseases (ORD)</lead_sponsor>
      <collaborator>The University of Texas Medical Branch, Galveston</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11796</other_id>
    </other_ids>
    <start_date>November 1999</start_date>
    <primary_completion_date>March 2009</primary_completion_date>
    <completion_date>March 2009</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 6, 2012</last_update_posted>
    <locations>
      <location>University of Texas Medical Branch at Galveston, Galveston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004306</url>
  </study>
  <study rank="327145">
    <nct_id>NCT00004305</nct_id>
    <title>Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IGA Glomerulonephritis</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>Ohio State University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11791</other_id>
      <other_id>OSU-94H0338</other_id>
    </other_ids>
    <start_date>January 1998</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Ohio State University, Columbus, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004305</url>
  </study>
  <study rank="327146">
    <nct_id>NCT00004300</nct_id>
    <title>Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stereotyped Behavior</condition>
      <condition>Mental Retardation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">bromocriptine</intervention>
      <intervention type="Drug">sertraline hydrochloride</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</lead_sponsor>
      <collaborator>University of Florida</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11754</other_id>
      <other_id>UF-63394</other_id>
    </other_ids>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>October 6, 2010</last_update_posted>
    <locations>
      <location>Western Carolina Center, Morganton, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004300</url>
  </study>
  <study rank="327147">
    <nct_id>NCT00004297</nct_id>
    <title>Phase III Randomized Study of Diazepam Vs Lorazepam Vs Placebo for Prehospital Treatment of Status Epilepticus</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Status Epilepticus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">diazepam</intervention>
      <intervention type="Drug">lorazepam</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>University of California, San Francisco</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11733</other_id>
      <other_id>UCSF-69020732504A</other_id>
    </other_ids>
    <start_date>November 1995</start_date>
    <completion_date>February 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004297</url>
  </study>
  <study rank="327148">
    <nct_id>NCT00004296</nct_id>
    <title>Multicenter Study of Nontuberculous Mycobacteria in Cystic Fibrosis Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
      <condition>Atypical Mycobacterium Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of North Carolina</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Screening</study_design>
      <study_design>Time Perspective: Longitudinal</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11731</other_id>
      <other_id>UNCCH-939</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004296</url>
  </study>
  <study rank="327149">
    <nct_id>NCT00004294</nct_id>
    <title>Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gaucher's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">human glucocerebrosidase gene into autologous peripheral blood stem cells</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11727</other_id>
      <other_id>UPITTS-GAUCHER</other_id>
    </other_ids>
    <start_date>November 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Pittsburgh, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004294</url>
  </study>
  <study rank="327150">
    <nct_id>NCT00004293</nct_id>
    <title>Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gaucher's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">glucocerebrosidase</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11725</other_id>
      <other_id>UPITTS-M1230</other_id>
    </other_ids>
    <start_date>November 1999</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of Pittsburgh, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004293</url>
  </study>
  <study rank="327151">
    <nct_id>NCT00004288</nct_id>
    <title>Phase II Pilot Study of Olsalazine for Ankylosing Spondylitis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ankylosing Spondylitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">olsalazine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Rochester</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11716</other_id>
      <other_id>URMC-44</other_id>
    </other_ids>
    <start_date>May 1996</start_date>
    <completion_date>December 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004288</url>
  </study>
  <study rank="327152">
    <nct_id>NCT00004287</nct_id>
    <title>Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">H5.001CBCFTR</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11715</other_id>
      <other_id>UPHS-28051</other_id>
    </other_ids>
    <start_date>November 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004287</url>
  </study>
  <study rank="327153">
    <nct_id>NCT00004286</nct_id>
    <title>Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">immune globulin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11713</other_id>
      <other_id>UVT-535</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <completion_date>November 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004286</url>
  </study>
  <study rank="327154">
    <nct_id>NCT00004285</nct_id>
    <title>Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis</title>
    <acronym>HEMO</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Standard dose, low flux hemodialysis</intervention>
      <intervention type="Device">Standard dose, high flux hemodialysis</intervention>
      <intervention type="Device">High dose, low flux hemodialysis</intervention>
      <intervention type="Device">High dose, high flux hemodialysis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Death from any cause</outcome_measure>
      <outcome_measure>First hospitalization for cardiac causes or death from any cause</outcome_measure>
      <outcome_measure>First hospitalization for infection or death from any cause</outcome_measure>
      <outcome_measure>First &gt;15% decrease in albumin or death from any cause</outcome_measure>
      <outcome_measure>All hospitalizations not related to vascular access</outcome_measure>
      <outcome_measure>Death due to cardiac causes</outcome_measure>
      <outcome_measure>First hospitalization or death due to cardiac causes</outcome_measure>
      <outcome_measure>Death due to infection</outcome_measure>
      <outcome_measure>First hospitalization or death due to infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>University of Rochester</collaborator>
      <collaborator>The Cleveland Clinic</collaborator>
      <collaborator>Tufts Medical Center</collaborator>
      <collaborator>Vanderbilt University</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center</collaborator>
      <collaborator>Washington University School of Medicine</collaborator>
      <collaborator>University of Illinois at Chicago</collaborator>
      <collaborator>Main Line Health</collaborator>
      <collaborator>Emory University</collaborator>
      <collaborator>Duke University</collaborator>
      <collaborator>University of Texas Southwestern Medical Center</collaborator>
      <collaborator>Brigham and Women's Hospital</collaborator>
      <collaborator>Wake Forest University Health Sciences</collaborator>
      <collaborator>University of Utah</collaborator>
      <collaborator>University of California, Davis</collaborator>
      <collaborator>University of Alabama at Birmingham</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1846</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11704</other_id>
      <other_id>U01DK046109</other_id>
      <other_id>U01DK046114</other_id>
      <other_id>U01DK046126</other_id>
      <other_id>U01DK046140</other_id>
      <other_id>U01DK046143</other_id>
      <other_id>U01DK049240</other_id>
      <other_id>U01DK049241</other_id>
      <other_id>U01DK049242</other_id>
      <other_id>U01DK049243</other_id>
      <other_id>U01DK049244</other_id>
      <other_id>U01DK049249</other_id>
      <other_id>U01DK049252</other_id>
      <other_id>U01DK049254</other_id>
      <other_id>U01DK049259</other_id>
      <other_id>U01DK049261</other_id>
      <other_id>U01DK049264</other_id>
      <other_id>U01DK049271</other_id>
    </other_ids>
    <start_date>March 1995</start_date>
    <primary_completion_date>December 31, 2001</primary_completion_date>
    <completion_date>December 31, 2001</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 14, 2017</last_update_posted>
    <locations>
      <location>University of Rochester School of Medicine, Rochester, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004285</url>
  </study>
  <study rank="327155">
    <nct_id>NCT00004284</nct_id>
    <title>Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypercalciuria</condition>
      <condition>Kidney Calculi</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">potassium citrate</intervention>
      <intervention type="Drug">potassium phosphate</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
      <collaborator>University of Texas</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11703</other_id>
      <other_id>UTSMC-039510400</other_id>
    </other_ids>
    <start_date>April 1995</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004284</url>
  </study>
  <study rank="327156">
    <nct_id>NCT00004278</nct_id>
    <title>Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cytomegalovirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ganciclovir</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Month</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11689</other_id>
      <other_id>NIAID-558607</other_id>
    </other_ids>
    <start_date>December 1991</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004278</url>
  </study>
  <study rank="327157">
    <nct_id>NCT00004276</nct_id>
    <title>Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Mycobacterium Infections</condition>
      <condition>Tuberculosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thalidomide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>Rockefeller University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11682</other_id>
      <other_id>RU-0300395</other_id>
    </other_ids>
    <start_date>September 1990</start_date>
    <completion_date>June 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004276</url>
  </study>
  <study rank="327158">
    <nct_id>NCT00004275</nct_id>
    <title>Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Turner's Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">growth hormone</intervention>
      <intervention type="Drug">oxandrolone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>Jefferson Medical College of Thomas Jefferson University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>10 Years</min_age>
    <max_age>14 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11681</other_id>
      <other_id>TJU-11681</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <primary_completion_date>August 2007</primary_completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>September 10, 2008</last_update_posted>
    <locations>
      <location>Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004275</url>
  </study>
  <study rank="327159">
    <nct_id>NCT00004274</nct_id>
    <title>Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Turner's Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Estrogen</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>Jefferson Medical College of Thomas Jefferson University</collaborator>
      <collaborator>Office of Rare Diseases (ORD)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>8 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11680</other_id>
      <other_id>TJU-11680</other_id>
    </other_ids>
    <start_date>February 1990</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004274</url>
  </study>
  <study rank="327160">
    <nct_id>NCT00004268</nct_id>
    <title>Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Orthostatic Hypotension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">midodrine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Center for Research Resources (NCRR)</lead_sponsor>
      <collaborator>Roberts Pharmaceutical</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11645</other_id>
      <other_id>RLI-5894009</other_id>
    </other_ids>
    <start_date>April 2001</start_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Mount Sinai School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004268</url>
  </study>
  <study rank="327161">
    <nct_id>NCT00004266</nct_id>
    <title>Drugs for High Blood Pressure and High Cholesterol in American Indians With Type 2 Diabetes</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Nephropathy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lisinopril</intervention>
      <intervention type="Drug">Nifedipine</intervention>
      <intervention type="Drug">Simvastatin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>Hennepin County Medical Center, Minneapolis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>199/11643</other_id>
      <other_id>UMN-1967</other_id>
      <other_id>R01DK047112</other_id>
    </other_ids>
    <start_date>August 1993</start_date>
    <primary_completion_date>July 1999</primary_completion_date>
    <completion_date>July 1999</completion_date>
    <study_first_posted>October 19, 1999</study_first_posted>
    <last_update_posted>March 7, 2018</last_update_posted>
    <locations>
      <location>Hennepin County Medical Center, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004266</url>
  </study>
  <study rank="327162">
    <nct_id>NCT00000170</nct_id>
    <title>Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amblyopia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atropine</intervention>
      <intervention type="Device">Eye Patch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Visual acuity in the amblyopic eye</outcome_measure>
      <outcome_measure>Extended Follow-up: (Primary) To determine the long-term visual acuity outcome at age 10 years and at age 15 years in patients diagnosed with amblyopia before age 7 years</outcome_measure>
      <outcome_measure>Extended Follow-up: To determine whether the long-term visual acuity outcome at age 10 yrs and age 15 yrs differs between patients who received patching followed by best clinical care and patients who received atropine followed by best clinical care</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jaeb Center for Health Research</lead_sponsor>
      <collaborator>National Eye Institute (NEI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>6 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>419</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-73</other_id>
      <other_id>2U10EY011751</other_id>
      <other_id>5U10EY011751</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <primary_completion_date>November 2001</primary_completion_date>
    <completion_date>August 2013</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>March 6, 2014</last_update_posted>
    <locations>
      <location>Wilmer Eye Institute, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000170</url>
  </study>
  <study rank="327163">
    <nct_id>NCT00000169</nct_id>
    <title>The Collaborative Longitudinal Evaluation of Ethnicity and Refractive Error (CLEERE) Study</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myopia</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>14 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NEI-72</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>West Alabama Health Services, Inc., Eutaw, Alabama, United States</location>
      <location>Southern California College of Optometry, Fullerton, California, United States</location>
      <location>University of Houston, College of Optometry, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000169</url>
  </study>
  <study rank="327164">
    <nct_id>NCT00000168</nct_id>
    <title>Longitudinal Study of Ocular Complications of AIDS (LSOCA)</title>
    <acronym>LSOCA</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Acquired Immunodeficiency Syndrome</condition>
      <condition>Cytomegalovirus Retinitis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>incidence of CMV retinitis, other ocular complications, mortality.</outcome_measure>
      <outcome_measure>incidence of sequelae of AIDS-related eye disease (e.g., retinal detachments), incidence of complications of therapy, and long-term outcomes of ocular complications (e.g., visual function, quality of life).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>National Eye Institute (NEI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2392</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-71</other_id>
      <other_id>5U10EY008057</other_id>
    </other_ids>
    <start_date>August 1998</start_date>
    <primary_completion_date>August 2013</primary_completion_date>
    <completion_date>August 2013</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 12, 2015</last_update_posted>
    <locations>
      <location>University of California, Irvine, Irvine, California, United States</location>
      <location>Shiley Eye Center, 0946, La Jolla, California, United States</location>
      <location>University of Southern California, Los Angeles, California, United States</location>
      <location>Jules Stein Eye Institute, Los Angeles, California, United States</location>
      <location>Francis I. Proctor Foundation, San Francisco, California, United States</location>
      <location>Bascom Palmer Eye Institute, Miami, Florida, United States</location>
      <location>University of South Florida, Tampa, Florida, United States</location>
      <location>Emory Eye Clinic, Atlanta, Georgia, United States</location>
      <location>Northwestern University, Chicago, Illinois, United States</location>
      <location>Division of Infectious Diseases, University of Indiana, Indianapolis, Indianapolis, Indiana, United States</location>
      <location>LSU Eye Center, New Orleans, Louisiana, United States</location>
      <location>The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States</location>
      <location>UMDNJ-New Jersey Medical School, Newark, New Jersey, United States</location>
      <location>Department of Ophthalmology, New York, New York, United States</location>
      <location>Department of Ophthalmology, New York, New York, United States</location>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
      <location>Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
      <location>University of Texas Medical Branch, Galveston, Texas, United States</location>
      <location>Cullen Eye Institute, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000168</url>
  </study>
  <study rank="327165">
    <nct_id>NCT00000167</nct_id>
    <title>Complications of Age-Related Macular Degeneration Prevention Trial</title>
    <acronym>CAPT</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Degeneration</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Low-Intensity Laser Treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in visual acuity (3-line loss)</outcome_measure>
      <outcome_measure>Incidence of complications of AMD such as neovascularization, serous detachment of the pigment epithelium, and geographic atrophy</outcome_measure>
      <outcome_measure>Changes in contrast threshold and critical print size for reading</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1052</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-70</other_id>
    </other_ids>
    <start_date>May 1999</start_date>
    <completion_date>June 2006</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>March 24, 2010</last_update_posted>
    <locations>
      <location>Retinal Consultants of Arizona, Ltd., Mesa, Arizona, United States</location>
      <location>Retinal Consultants of Arizona, Ltd., Peoria, Arizona, United States</location>
      <location>West Coast Retina Medical Group, Inc., San Francisco, California, United States</location>
      <location>University of South Florida Eye Institute, Tampa, Florida, United States</location>
      <location>Emory Eye Center, Atlanta, Georgia, United States</location>
      <location>Northwestern University, Chicago, Illinois, United States</location>
      <location>Illinois Retina Associates, S.C., Harvey, Illinois, United States</location>
      <location>University of Iowa, Iowa City, Iowa, United States</location>
      <location>Ophthalmology &amp; Visual Sciences at the University of Louisville, School of Medicine, Louisville, Kentucky, United States</location>
      <location>The Johns Hopkins University, Baltimore, Maryland, United States</location>
      <location>Ophthalmic Consultants of Boston, Boston, Massachusetts, United States</location>
      <location>Associate Retinal Consultants, P.C., Royal Oak, Michigan, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Barnes Retina Institute, St. Louis, Missouri, United States</location>
      <location>Retina-Vitreous Center, P.A., Edison, New Jersey, United States</location>
      <location>Retina-Vitreous Center, P.A., Lakewood, New Jersey, United States</location>
      <location>Southeast Clinical Research Associates, Charlotte, North Carolina, United States</location>
      <location>Retina Associates of Cleveland, Cleveland, Ohio, United States</location>
      <location>The Ohio State University, Department of Ophthalmology, Columbus, Ohio, United States</location>
      <location>Casey Eye Institute, Portland, Oregon, United States</location>
      <location>Retina Northwest, P.C., Portland, Oregon, United States</location>
      <location>Scheie Eye Institute, Philadelphia, Pennsylvania, United States</location>
      <location>Texas Retina Associates, Dallas, Texas, United States</location>
      <location>University of Wisconsin - Madison, Department of Ophthalmology and Visual Sciences, Madison, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000167</url>
  </study>
  <study rank="327166">
    <nct_id>NCT00000163</nct_id>
    <title>Congenital Esotropia Observational Study (CEOS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Esotropia</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>20 Weeks</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NEI-65</other_id>
    </other_ids>
    <start_date>December 1997</start_date>
    <completion_date>July 2000</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000163</url>
  </study>
  <study rank="327167">
    <nct_id>NCT00000162</nct_id>
    <title>Branch Vein Occlusion Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Degeneration</condition>
      <condition>Neovascularization, Pathologic</condition>
      <condition>Vitreous Hemorrhage</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Macular Argon Laser Photocoagulation</intervention>
      <intervention type="Procedure">Peripheral Scatter Argon Laser Photocoagulation</intervention>
      <intervention type="Procedure">Scatter Argon Laser Photocoagulation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-64</other_id>
    </other_ids>
    <start_date>July 1977</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000162</url>
  </study>
  <study rank="327168">
    <nct_id>NCT00000161</nct_id>
    <title>Randomized Trials of Vitamin Supplements and Eye Disease</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Degeneration</condition>
      <condition>Cataract</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin</intervention>
      <intervention type="Drug">Beta-Carotene</intervention>
      <intervention type="Drug">Vitamin C</intervention>
      <intervention type="Drug">Vitamin E</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-63</other_id>
    </other_ids>
    <start_date>August 1993</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000161</url>
  </study>
  <study rank="327169">
    <nct_id>NCT00000160</nct_id>
    <title>Diabetic Retinopathy Study (DRS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Retinopathy</condition>
      <condition>Blindness</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Xenon Photocoagulation</intervention>
      <intervention type="Procedure">Argon Photocoagulation</intervention>
      <intervention type="Procedure">Photocoagulation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-62</other_id>
    </other_ids>
    <start_date>January 1972</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 2, 2006</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000160</url>
  </study>
  <study rank="327170">
    <nct_id>NCT00000159</nct_id>
    <title>Sorbinil Retinopathy Trial (SRT)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Retinopathy</condition>
      <condition>Diabetes Mellitus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sorbinil</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>56 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-61</other_id>
    </other_ids>
    <start_date>August 1983</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000159</url>
  </study>
  <study rank="327171">
    <nct_id>NCT00000158</nct_id>
    <title>Macular Photocoagulation Study (MPS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Choroidal Neovascularization</condition>
      <condition>Macular Degeneration</condition>
      <condition>Histoplasmosis</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Argon Blue-Green Laser Photocoagulation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-60</other_id>
    </other_ids>
    <start_date>February 1979</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000158</url>
  </study>
  <study rank="327172">
    <nct_id>NCT00000157</nct_id>
    <title>Randomized Trial of Aspirin and Cataracts in U.S. Physicians</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cataract</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>40 Years</min_age>
    <max_age>84 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-59</other_id>
    </other_ids>
    <start_date>April 1982</start_date>
    <completion_date>January 1988</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000157</url>
  </study>
  <study rank="327173">
    <nct_id>NCT00000156</nct_id>
    <title>The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Retinopathy of Prematurity</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Goggles</intervention>
      <intervention type="Procedure">Ambient Light Reduction</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Day</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-58</other_id>
    </other_ids>
    <start_date>July 1995</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 5, 2006</last_update_posted>
    <locations>
      <location>The Children's Hospital of Buffalo, Buffalo, New York, United States</location>
      <location>The University of Texas, Southwestern Medical Center at Dallas, Dallas, Texas, United States</location>
      <location>University of Texas, Health Science Center, San Antonio, San Antonio, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000156</url>
  </study>
  <study rank="327174">
    <nct_id>NCT00000155</nct_id>
    <title>The Collaborative Longitudinal Evaluation of Keratoconus (CLEK) Study</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Keratoconus</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-57</other_id>
    </other_ids>
    <start_date>June 1995</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>University of California, Berkeley, School of Optometry, Berkeley, California, United States</location>
      <location>Southern California College of Optometry, Fullerton, California, United States</location>
      <location>Jules Stein Eye Institute, University of California at Los Angeles, Los Angeles, California, United States</location>
      <location>Nova Southeastern University, Health Professions Division, College of Optometry, Ft. Lauderdale, Florida, United States</location>
      <location>University of Illinois at Chicago, Department of Ophthalmology and Visual Sciences, Chicago, Illinois, United States</location>
      <location>Indiana University, School of Optometry, Bloomington, Indiana, United States</location>
      <location>University of Missouri-St. Louis, School of Optometry, St. Louis, Missouri, United States</location>
      <location>SUNY State College of Optometry, New York, New York, United States</location>
      <location>University Hospitals of Cleveland, Department of Ophthalmology, Cleveland, Ohio, United States</location>
      <location>The Ohio State University, College of Optometry, Columbus, Ohio, United States</location>
      <location>Pennsylvania College of Optometry, The Eye Institute, Philadelphia, Pennsylvania, United States</location>
      <location>Northeastern Eye Institute, Scranton, Pennsylvania, United States</location>
      <location>University of Utah, John Moran Eye Center, Salt Lake City, Utah, United States</location>
      <location>Gundersen Lutheran, La Crosse, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000155</url>
  </study>
  <study rank="327175">
    <nct_id>NCT00000154</nct_id>
    <title>Diabetic Retinopathy Vitrectomy Study (DRVS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Retinopathy</condition>
      <condition>Retinal Detachment</condition>
      <condition>Vitreous Hemorrhage</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Vitrectomy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-56</other_id>
    </other_ids>
    <start_date>October 1976</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000154</url>
  </study>
  <study rank="327176">
    <nct_id>NCT00000153</nct_id>
    <title>Krypton-Argon Regression of Neovascularization Study (KARNS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetic Retinopathy</condition>
      <condition>Retinal Neovascularization</condition>
      <condition>Diabetes Mellitus</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Blue-Green Argon Laser Treatment</intervention>
      <intervention type="Procedure">Red Krypton Laser Treatment</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-55</other_id>
    </other_ids>
    <start_date>December 1984</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000153</url>
  </study>
  <study rank="327177">
    <nct_id>NCT00000152</nct_id>
    <title>Randomized Trial of Beta-Carotene and Macular Degeneration</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Degeneration</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin</intervention>
      <intervention type="Drug">Beta-Carotene</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>40 Years</min_age>
    <max_age>84 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-54</other_id>
    </other_ids>
    <start_date>April 1982</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000152</url>
  </study>
  <study rank="327178">
    <nct_id>NCT00000151</nct_id>
    <title>Early Treatment Diabetic Retinopathy Study (ETDRS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Blindness</condition>
      <condition>Diabetic Retinopathy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin</intervention>
      <intervention type="Procedure">Argon Laser Photocoagulation</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-53</other_id>
    </other_ids>
    <start_date>December 1979</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 4, 2006</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000151</url>
  </study>
  <study rank="327179">
    <nct_id>NCT00000150</nct_id>
    <title>Submacular Surgery Trials (SST)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Degeneration</condition>
      <condition>Histoplasmosis</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Subfoveal Choroidal Neovascularization Removal</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-52</other_id>
    </other_ids>
    <start_date>January 1999</start_date>
    <completion_date>September 2001</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000150</url>
  </study>
  <study rank="327180">
    <nct_id>NCT00000149</nct_id>
    <title>Collaborative Initial Glaucoma Treatment Study (CIGTS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Open-Angle Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Beta Blocker</intervention>
      <intervention type="Procedure">Trabeculectomy</intervention>
      <intervention type="Procedure">Argon Laser Trabeculoplasty</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-50</other_id>
    </other_ids>
    <start_date>October 1993</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000149</url>
  </study>
  <study rank="327181">
    <nct_id>NCT00000148</nct_id>
    <title>Advanced Glaucoma Intervention Study (AGIS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Argon Laser Trabeculoplasty</intervention>
      <intervention type="Procedure">Trabeculectomy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-49</other_id>
    </other_ids>
    <start_date>April 1988</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 5, 2006</last_update_posted>
    <locations>
      <location>Yale University School of Medicine, Yale Eye Center, New Haven, Connecticut, United States</location>
      <location>Georgetown University, University Ophthalmic Consultants of Washington, Eye Associates of Washington, D.C., Washington, District of Columbia, United States</location>
      <location>Emory University, Emory Eye Center, Atlanta, Georgia, United States</location>
      <location>Piedmont Hospital, Eye Consultants of Atlanta, Atlanta, Georgia, United States</location>
      <location>Humana Health Plan Sykes Center, Chicago, Illinois, United States</location>
      <location>University of Illinois, Eye and Ear Infirmary, Chicago, Illinois, United States</location>
      <location>Washington Hospital Center, Washington Eye Physicians and Surgeons, Chevy Chase, Maryland, United States</location>
      <location>University of Michigan, W.K. Kellogg Eye Center, Ann Arbor, Michigan, United States</location>
      <location>Sinai Hospital, Detroit, Franklin Eye Consultants, Southfield, Michigan, United States</location>
      <location>Ohio State University, Department of Ophthalmology, Ophthalmic Surgeons and Consultants, Columbus, Ohio, United States</location>
      <location>Wills Eye Hospital, Glaucoma Service, Philadelphia, Pennsylvania, United States</location>
      <location>University of Virginia Medical Center, Department of Ophthalmology, Charlottesville, Virginia, United States</location>
      <location>Medical College of Virginia, Department of Ophthalmology, Richmond, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000148</url>
  </study>
  <study rank="327182">
    <nct_id>NCT00000147</nct_id>
    <title>Longitudinal Optic Neuritis Study (LONS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
      <condition>Optic Neuritis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">Prednisone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>46 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-48</other_id>
    </other_ids>
    <start_date>July 1988</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>May 29, 2006</last_update_posted>
    <locations>
      <location>University of Arkansas, Little Rock, Arkansas, United States</location>
      <location>California Pacific Medical Center, San Francisco, California, United States</location>
      <location>Georgetown University, Washington, District of Columbia, United States</location>
      <location>University of Florida, Gainesville, Florida, United States</location>
      <location>University of Illinois, Chicago, Illinois, United States</location>
      <location>University of Iowa, Iowa City, Iowa, United States</location>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Michigan State University, East Lansing, Michigan, United States</location>
      <location>New York University, New York, New York, United States</location>
      <location>Duke University, Durham, North Carolina, United States</location>
      <location>Devers Eye Institute, Portland, Oregon, United States</location>
      <location>Wills Eye Hospital, Philadelphia, Pennsylvania, United States</location>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
      <location>Swedish Medical Center, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000147</url>
  </study>
  <study rank="327183">
    <nct_id>NCT00000146</nct_id>
    <title>Optic Neuritis Treatment Trial (ONTT)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
      <condition>Optic Neuritis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">Prednisone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>46 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-47</other_id>
    </other_ids>
    <start_date>July 1988</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 5, 2006</last_update_posted>
    <locations>
      <location>University of Arkansas, Little Rock, Arkansas, United States</location>
      <location>California Pacific Medical Center, San Francisco, California, United States</location>
      <location>Georgetown University, Washington, District of Columbia, United States</location>
      <location>University of Florida, Gainesville, Florida, United States</location>
      <location>University of Illinois, Chicago, Illinois, United States</location>
      <location>University of Iowa, Iowa City, Iowa, United States</location>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
      <location>University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Michigan State University, East Lansing, Michigan, United States</location>
      <location>New York University, New York, New York, United States</location>
      <location>Duke University, Durham, North Carolina, United States</location>
      <location>Devers Eye Institute, Portland, Oregon, United States</location>
      <location>Wills Eye Hospital, Philadelphia, Pennsylvania, United States</location>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
      <location>Swedish Medical Center, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000146</url>
  </study>
  <study rank="327184">
    <nct_id>NCT00000145</nct_id>
    <title>Age-Related Eye Disease Study (AREDS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Degeneration</condition>
      <condition>Cataract</condition>
      <condition>Lens Opacities</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Antioxidants</intervention>
      <intervention type="Dietary Supplement">Zinc</intervention>
      <intervention type="Dietary Supplement">Antioxidants and zinc</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression of age-related macular degeneration</outcome_measure>
      <outcome_measure>Progression of lens opacity (cataract)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
      <collaborator>Bausch &amp; Lomb Incorporated</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>55 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4757</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-44</other_id>
    </other_ids>
    <start_date>September 1990</start_date>
    <primary_completion_date>October 2001</primary_completion_date>
    <completion_date>December 2006</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>January 23, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000145</url>
  </study>
  <study rank="327185">
    <nct_id>NCT00000144</nct_id>
    <title>Glaucoma Laser Trial (GLT) Glaucoma Laser Trial Followup Study (GLTFS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Open-Angle Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Argon Laser Treatment</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-43</other_id>
    </other_ids>
    <start_date>January 1984</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 5, 2006</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000144</url>
  </study>
  <study rank="327186">
    <nct_id>NCT00000143</nct_id>
    <title>Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)</title>
    <acronym>GCCRT</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Cytomegalovirus Retinitis</condition>
      <condition>HIV Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Ganciclovir implant and oral ganciclovir</intervention>
      <intervention type="Drug">Cidofovir intravenous</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-42</other_id>
    </other_ids>
    <start_date>May 1997</start_date>
    <primary_completion_date>June 2000</primary_completion_date>
    <completion_date>June 2000</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <results_first_posted>March 14, 2016</results_first_posted>
    <last_update_posted>March 14, 2016</last_update_posted>
    <locations>
      <location>Department of Ophthalmology, University of California, Irvine, Irvine, California, United States</location>
      <location>Shiley Eye Center Center, 0946, University of California, San Diego, La Jolla, California, United States</location>
      <location>LAC/USC Medical Center, 5P21 Rand Schrader Clinic, Los Angeles, California, United States</location>
      <location>Jules Stein Eye Institute, University of California, Los Angeles, Los Angeles, California, United States</location>
      <location>Beckman Vision Center, University of California, San Francisco, San Francisco, California, United States</location>
      <location>Bascom Palmer Eye Institute, University of Miami, Miami, Florida, United States</location>
      <location>University of South Florida, MDC Box 21, Tampa, Florida, United States</location>
      <location>The Emory Clinic, Emory University, Atlanta, Georgia, United States</location>
      <location>Department of Ophthalmology, Northwestern University, Chicago, Illinois, United States</location>
      <location>Division of Infectious Diseases, Indiana University, Indianapolis, Indianapolis, Indiana, United States</location>
      <location>LSU Eye Center, Louisiana State University Medical Center, New Orleans, Louisiana, United States</location>
      <location>The Wilmer Ophthalmological Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States</location>
      <location>Harvard/BCH AIDS Clinical Trials Unit, Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>UMDNJ-New Jersey Medical School, Newark, New Jersey, United States</location>
      <location>Department of Ophthalmology, New York University Medical Center, New York, New York, United States</location>
      <location>Department of Ophthalmology, New York Hospital-Cornell Medical Center, New York, New York, United States</location>
      <location>Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, United States</location>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
      <location>Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000143</url>
  </study>
  <study rank="327187">
    <nct_id>NCT00000142</nct_id>
    <title>Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)</title>
    <acronym>HPCRT</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>CMV Cytomegalovirus Retinitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cidofovir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>Baylor College of Medicine</collaborator>
      <collaborator>Johns Hopkins University</collaborator>
      <collaborator>Louisiana State University Health Sciences Center in New Orleans</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>New Jersey Medical School</collaborator>
      <collaborator>NYU Langone Health</collaborator>
      <collaborator>Northwestern University</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>University of California, San Francisco</collaborator>
      <collaborator>University of Miami</collaborator>
      <collaborator>University of North Carolina, Chapel Hill</collaborator>
      <collaborator>University of South Florida</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-41</other_id>
    </other_ids>
    <start_date>April 1994</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>February 1996</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <results_first_posted>November 17, 2015</results_first_posted>
    <last_update_posted>November 17, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000142</url>
  </study>
  <study rank="327188">
    <nct_id>NCT00000140</nct_id>
    <title>The Silicone Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Proliferative Vitreoretinopathy</condition>
      <condition>Retinal Detachment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Perfluoropropane</intervention>
      <intervention type="Drug">Sulfur Hexafluoride</intervention>
      <intervention type="Drug">Silicone Oil</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-39</other_id>
    </other_ids>
    <start_date>September 1985</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000140</url>
  </study>
  <study rank="327189">
    <nct_id>NCT00000139</nct_id>
    <title>Herpetic Eye Disease Study (HEDS) II</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Keratitis, Herpetic</condition>
      <condition>Ocular Herpes Simplex</condition>
      <condition>Herpes Simplex</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Stress</intervention>
      <intervention type="Drug">Acyclovir</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-38</other_id>
    </other_ids>
    <start_date>October 1992</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>March 24, 2010</last_update_posted>
    <locations>
      <location>Francis I. Proctor Foundation, University of California, San Francisco, San Francisco, California, United States</location>
      <location>Emory Eye Center, Atlanta, Georgia, United States</location>
      <location>Eye Center, University of Illinois, Chicago, Chicago, Illinois, United States</location>
      <location>Louisiana State University Eye Center, New Orleans, Louisiana, United States</location>
      <location>Department of Ophthalmology, The Mount Sinai Medical Center, New York, New York, United States</location>
      <location>Wills Eye Hospital, Cornea Clinic, Philadelphia, Pennsylvania, United States</location>
      <location>Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, United States</location>
      <location>The Eye Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000139</url>
  </study>
  <study rank="327190">
    <nct_id>NCT00000138</nct_id>
    <title>Herpetic Eye Disease Study (HEDS) I</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Keratitis, Herpetic</condition>
      <condition>Ocular Herpes Simplex</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prednisolone Phosphate</intervention>
      <intervention type="Drug">Acyclovir</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-37</other_id>
    </other_ids>
    <start_date>May 1989</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000138</url>
  </study>
  <study rank="327191">
    <nct_id>NCT00000137</nct_id>
    <title>Collaborative Corneal Transplantation Studies (CCTS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corneal Transplantation</condition>
      <condition>Graft Rejection</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Histocompatibility Matching</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-36</other_id>
    </other_ids>
    <start_date>May 1986</start_date>
    <completion_date>September 1989</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000137</url>
  </study>
  <study rank="327192">
    <nct_id>NCT00000136</nct_id>
    <title>Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)</title>
    <acronym>FGCRT</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Cytomegalovirus Retinitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Foscarnet</intervention>
      <intervention type="Drug">Ganciclovir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>National Eye Institute (NEI)</collaborator>
      <collaborator>Johns Hopkins University</collaborator>
      <collaborator>University of Wisconsin, Madison</collaborator>
      <collaborator>Baylor College of Medicine</collaborator>
      <collaborator>Louisiana State University Health Sciences Center in New Orleans</collaborator>
      <collaborator>New York Presbyterian Hospital</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>NYU Langone Health</collaborator>
      <collaborator>Northwestern University</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>University of California, San Francisco</collaborator>
      <collaborator>University of Miami</collaborator>
      <collaborator>University of Massachusetts, Worcester</collaborator>
      <collaborator>Memorial Sloan Kettering Cancer Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>234</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-35</other_id>
      <other_id>U10EY008057</other_id>
    </other_ids>
    <start_date>March 1990</start_date>
    <primary_completion_date>October 1991</primary_completion_date>
    <completion_date>October 1991</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <results_first_posted>October 22, 2015</results_first_posted>
    <last_update_posted>October 22, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000136</url>
  </study>
  <study rank="327193">
    <nct_id>NCT00000135</nct_id>
    <title>Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT)</title>
    <acronym>MACRT</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Cytomegalovirus Retinitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MSL-109</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>209</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-34</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <primary_completion_date>August 1996</primary_completion_date>
    <completion_date>August 1996</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <results_first_posted>November 17, 2015</results_first_posted>
    <last_update_posted>November 17, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000135</url>
  </study>
  <study rank="327194">
    <nct_id>NCT00000134</nct_id>
    <title>Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)</title>
    <acronym>CRRT</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Acquired Immunodeficiency Syndrome</condition>
      <condition>Cytomegalovirus Retinitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ganciclovir</intervention>
      <intervention type="Drug">Foscarnet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Morbidity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins Bloomberg School of Public Health</lead_sponsor>
      <collaborator>National Eye Institute (NEI)</collaborator>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
      <collaborator>Johns Hopkins University</collaborator>
      <collaborator>University of Wisconsin, Madison</collaborator>
      <collaborator>Baylor College of Medicine</collaborator>
      <collaborator>Tulane University School of Medicine</collaborator>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
      <collaborator>New York Presbyterian Hospital</collaborator>
      <collaborator>New York University</collaborator>
      <collaborator>Northwestern University</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
      <collaborator>University of California, San Francisco</collaborator>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>University of Miami</collaborator>
      <collaborator>University of North Carolina, Chapel Hill</collaborator>
      <collaborator>Memorial Sloan Kettering Cancer Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>279</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-33</other_id>
      <other_id>U10EY008057</other_id>
      <other_id>U01AI027668</other_id>
    </other_ids>
    <start_date>December 1992</start_date>
    <primary_completion_date>March 1995</primary_completion_date>
    <completion_date>March 1995</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <results_first_posted>September 14, 2015</results_first_posted>
    <last_update_posted>September 14, 2015</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000134</url>
  </study>
  <study rank="327195">
    <nct_id>NCT00000133</nct_id>
    <title>Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) - Outcome Study of Cryotherapy for Retinopathy of Prematurity</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Retinopathy of Prematurity</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Trans-scleral Cryotherapy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Year</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-32</other_id>
    </other_ids>
    <start_date>January 1986</start_date>
    <completion_date>August 2003</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>February 4, 2014</last_update_posted>
    <locations>
      <location>Alabama Ophthalmology Associates, P.C., Birmingham, Alabama, United States</location>
      <location>Private practice of David Plotsky, MD, Washington, District of Columbia, United States</location>
      <location>Retina Group of Washington, Washington, District of Columbia, United States</location>
      <location>Bascom Palmer Eye Institute, University of Miami School of Medicine, Miami, Florida, United States</location>
      <location>University of Illinois Eye and Ear Infirmary, Chicago, Illinois, United States</location>
      <location>Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, United States</location>
      <location>Kentucky Lions Eye Research Institute, University of Louisville, Louisville, Kentucky, United States</location>
      <location>Department of Ophthalmology, Tulane University School of Medicine, New Orleans, Louisiana, United States</location>
      <location>Wilmer Eye Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, United States</location>
      <location>Private practice of John D. Baker, MD, Dearborn, Michigan, United States</location>
      <location>Associated Retinal Consultants, P.C., Royal Oak, Michigan, United States</location>
      <location>Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, United States</location>
      <location>Strong Children's Hospital, University of Rochester Medical Center, Rochester, New York, United States</location>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
      <location>Private Practice of Miles J. Burke, MD, Cincinnati, Ohio, United States</location>
      <location>Columbus Children's Hospital, Columbus, Ohio, United States</location>
      <location>Oregon Health &amp; Science University, Casey Eye Institute, Portland, Oregon, United States</location>
      <location>Children's Hospital of Philadelphia, Division of Pediatric Ophthalmology, Philadelphia, Pennsylvania, United States</location>
      <location>Pediatric Ophthalmology and Strabismus, Inc., Pittsburgh, Pennsylvania, United States</location>
      <location>Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina, United States</location>
      <location>Department of Ophthalmology, Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
      <location>Private practice of Rand Spencer, M.D., Dallas, Texas, United States</location>
      <location>University of Texas Health Science Center, San Antonio, Department of Ophthalmology, San Antonio, Texas, United States</location>
      <location>John Moran Eye Center, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000133</url>
  </study>
  <study rank="327196">
    <nct_id>NCT00000132</nct_id>
    <title>Early Manifest Glaucoma Trial (EMGT)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Open-Angle Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Betaxolol</intervention>
      <intervention type="Procedure">Argon Laser Trabeculoplasty</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-31</other_id>
    </other_ids>
    <start_date>October 1992</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Department of Ophthalmology, Helsingborg Hospital, Helsingborg, Sweden</location>
      <location>Department of Ophthalmology, Malmo University Hospital, University of Lund, Malmo, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000132</url>
  </study>
  <study rank="327197">
    <nct_id>NCT00000131</nct_id>
    <title>Central Vein Occlusion Study (CVOS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Retinal Vein Occlusion</condition>
      <condition>Retinal Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Photocoagulation Therapy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-30</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <completion_date>February 1994</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000131</url>
  </study>
  <study rank="327198">
    <nct_id>NCT00000130</nct_id>
    <title>Endophthalmitis Vitrectomy Study (EVS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Endophthalmitis</condition>
      <condition>Eye Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravitreal Antibiotics</intervention>
      <intervention type="Procedure">Initial Pars Plana Vitrectomy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-29</other_id>
    </other_ids>
    <start_date>February 1990</start_date>
    <completion_date>January 1995</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000130</url>
  </study>
  <study rank="327199">
    <nct_id>NCT00000129</nct_id>
    <title>Prospective Evaluation of Radial Keratotomy (PERK) Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myopia</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Radial Keratotomy</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-28</other_id>
    </other_ids>
    <start_date>April 1981</start_date>
    <completion_date>October 1983</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000129</url>
  </study>
  <study rank="327200">
    <nct_id>NCT00000128</nct_id>
    <title>A Trial of Bifocals in Myopic Children With Esophoria</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myopia</condition>
      <condition>Strabismus</condition>
      <condition>Esophoria</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Bifocal Spectacle Lenses</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-27</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000128</url>
  </study>
  <study rank="327201">
    <nct_id>NCT00000127</nct_id>
    <title>Ischemic Optic Neuropathy Decompression Trial (IONDT)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ischemic Optic Neuropathy</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Optic Nerve Sheath Decompression Surgery</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-26</other_id>
    </other_ids>
    <start_date>October 1992</start_date>
    <completion_date>October 1994</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>March 24, 2010</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000127</url>
  </study>
  <study rank="327202">
    <nct_id>NCT00000126</nct_id>
    <title>Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ischemic Optic Neuropathy</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Surgery</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Time Perspective: Longitudinal</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-25</other_id>
    </other_ids>
    <start_date>October 1994</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>May 26, 2006</last_update_posted>
    <locations>
      <location>Doheny Eye Institute, University of Southern California, Los Angeles, California, United States</location>
      <location>Jules Stein Eye Institute, Los Angeles, California, United States</location>
      <location>Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States</location>
      <location>Department of Ophthalmology, University of Florida, Gainesville, Florida, United States</location>
      <location>Emory Eye Center, Emory University, Atlanta, Georgia, United States</location>
      <location>Department of Ophthalmology, University of Illinois, Chicago, Illinois, United States</location>
      <location>Department of Ophthalmology, University of Kentucky, Lexington, Kentucky, United States</location>
      <location>University of Maryland, Baltimore, Maryland, United States</location>
      <location>W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States</location>
      <location>Department of Ophthalmology, Michigan State University, East Lansing, Michigan, United States</location>
      <location>William Beaumont Eye Institute, William Beaumont Hospital, Royal Oak, Michigan, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Mason Institute of Ophthalmology, University of Missouri - Columbia, Columbia, Missouri, United States</location>
      <location>St. Louis University, Anheuser-Busch Eye Institute, St. Louis, Missouri, United States</location>
      <location>SUNY Health Science Center, Department of Neurology, Syracuse, New York, United States</location>
      <location>Carolinas Medical Center, Charlotte, North Carolina, United States</location>
      <location>The Cleveland Clinic Foundation, Cleveland, Ohio, United States</location>
      <location>Allegheny General Hospital, Pittsburgh, Pennsylvania, United States</location>
      <location>University of South Carolina, Department of Ophthalmology, Columbia, South Carolina, United States</location>
      <location>University of Texas, Houston, Texas, United States</location>
      <location>University of Utah, Department of Ophthalmology, Salt Lake City, Utah, United States</location>
      <location>University of Virginia, Department of Ophthalmology, Charlottesville, Virginia, United States</location>
      <location>Medical College of Virginia, Department of Neurology, Richmond, Virginia, United States</location>
      <location>West Virginia University, Department of Neurology, Morgantown, West Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000126</url>
  </study>
  <study rank="327203">
    <nct_id>NCT00000125</nct_id>
    <title>Ocular Hypertension Treatment Study (OHTS)</title>
    <acronym>OHTS</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Ocular Hypertension</condition>
      <condition>Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Topical ocular hypotensive eye drops.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>National Eye Institute (NEI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1636</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-24</other_id>
      <other_id>5U10EY009307-16</other_id>
      <other_id>5U10EY009341-14</other_id>
    </other_ids>
    <start_date>February 1994</start_date>
    <primary_completion_date>June 2002</primary_completion_date>
    <completion_date>March 2020</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <results_first_posted>March 19, 2015</results_first_posted>
    <last_update_posted>September 17, 2019</last_update_posted>
    <locations/>
    <study_documents>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT00000125/ICF_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT00000125</url>
  </study>
  <study rank="327204">
    <nct_id>NCT00000124</nct_id>
    <title>Collaborative Ocular Melanoma Study (COMS)</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Choroid Neoplasms</condition>
      <condition>Uveitis</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Brachytherapy</intervention>
      <intervention type="Procedure">Eye Removal</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-23</other_id>
    </other_ids>
    <start_date>November 1986</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 2, 2006</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000124</url>
  </study>
  <study rank="327205">
    <nct_id>NCT00000123</nct_id>
    <title>The Berkeley Orthokeratology Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Astigmatism</condition>
      <condition>Myopia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Polymethyl Methacrylate-Silicone Contact Lenses</intervention>
      <intervention type="Device">Polymethyl Methacrylate Contact Lenses</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-22</other_id>
    </other_ids>
    <start_date>January 1978</start_date>
    <completion_date>February 1979</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000123</url>
  </study>
  <study rank="327206">
    <nct_id>NCT00000122</nct_id>
    <title>Fluorouracil Filtering Surgery Study (FFSS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">5-Fluorouracil</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-21</other_id>
    </other_ids>
    <start_date>September 1985</start_date>
    <completion_date>June 1988</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000122</url>
  </study>
  <study rank="327207">
    <nct_id>NCT00000121</nct_id>
    <title>The Prism Adaptation Study (PAS)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Esotropia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Prisms in Eyeglasses</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-20</other_id>
    </other_ids>
    <start_date>March 1984</start_date>
    <completion_date>May 1989</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000121</url>
  </study>
  <study rank="327208">
    <nct_id>NCT00000120</nct_id>
    <title>Clinical Trial of Eye Prophylaxis in the Newborn</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chlamydia Infections</condition>
      <condition>Ophthalmia Neonatorum</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Erythromycin Ointment</intervention>
      <intervention type="Drug">Silver Nitrate Drops</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Year</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-19</other_id>
    </other_ids>
    <start_date>January 1985</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000120</url>
  </study>
  <study rank="327209">
    <nct_id>NCT00000119</nct_id>
    <title>Safety and Efficacy of a Heparin-Coated Intraocular Lens in Uveitis</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cataract</condition>
      <condition>Uveitis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Heparin Surface-Modified Intraocular Lens</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-15</other_id>
    </other_ids>
    <start_date>March 1994</start_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>National Institutes of Health, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000119</url>
  </study>
  <study rank="327210">
    <nct_id>NCT00000118</nct_id>
    <title>Ganciclovir Implant Study for Cytomegalovirus Retinitis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Infections</condition>
      <condition>Acquired Immunodeficiency Syndrome</condition>
      <condition>Cytomegalovirus Retinitis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Sustained-Release Intraocular Drug Delivery System</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-14</other_id>
    </other_ids>
    <start_date>October 1992</start_date>
    <completion_date>December 1993</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000118</url>
  </study>
  <study rank="327211">
    <nct_id>NCT00000117</nct_id>
    <title>Intravenous Immunoglobulin Therapy in Optic Neuritis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Optic Neuritis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Immunoglobulin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-13</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <completion_date>December 1997</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations>
      <location>Mayo Clinic, Department of Neurology, Rochester, Minnesota, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000117</url>
  </study>
  <study rank="327212">
    <nct_id>NCT00000116</nct_id>
    <title>Randomized Trial for Retinitis Pigmentosa</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Retinitis Pigmentosa</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin A</intervention>
      <intervention type="Drug">Nutritional Supplement</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>56 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-12</other_id>
    </other_ids>
    <start_date>May 1996</start_date>
    <completion_date>September 1997</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations>
      <location>Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000116</url>
  </study>
  <study rank="327213">
    <nct_id>NCT00000115</nct_id>
    <title>Randomized Trial of Acetazolamide for Uveitis-Associated Cystoid Macular Edema</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Edema, Cystoid</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Acetazolamide</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-11</other_id>
    </other_ids>
    <start_date>December 1990</start_date>
    <completion_date>June 1994</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000115</url>
  </study>
  <study rank="327214">
    <nct_id>NCT00000114</nct_id>
    <title>Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Retinitis Pigmentosa</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin E</intervention>
      <intervention type="Drug">Vitamin A</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Eye Institute (NEI)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-10</other_id>
    </other_ids>
    <start_date>May 1984</start_date>
    <completion_date>June 1987</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>September 17, 2009</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000114</url>
  </study>
  <study rank="327215">
    <nct_id>NCT00000113</nct_id>
    <title>Correction of Myopia Evaluation Trial (COMET)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myopia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Progressive Addition Lenses</intervention>
      <intervention type="Other">single vision lenses</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression of myopia, determined by cycloplegic autorefraction</outcome_measure>
      <outcome_measure>Axial length measured by A-scan ultrasonography</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stony Brook University</lead_sponsor>
      <collaborator>National Eye Institute (NEI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>469</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NEI-9</other_id>
      <other_id>U10EY011756</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <primary_completion_date>October 2001</primary_completion_date>
    <completion_date>September 2013</completion_date>
    <study_first_posted>September 24, 1999</study_first_posted>
    <last_update_posted>April 15, 2016</last_update_posted>
    <locations>
      <location>University of Alabama-Birmingham, School of Optometry, Birmingham, Alabama, United States</location>
      <location>New England College of Optometry, Boston, Massachusetts, United States</location>
      <location>Pennsylvania College of Optometry, Philadelphia, Pennsylvania, United States</location>
      <location>University of Houston, College of Optometry, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000113</url>
  </study>
  <study rank="327216">
    <nct_id>NCT00000358</nct_id>
    <title>Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lofexidine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-7</other_id>
      <other_id>Y01-3-0012-7</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000358</url>
  </study>
  <study rank="327217">
    <nct_id>NCT00000357</nct_id>
    <title>Buprenorphine Maintenance for Opiate Dependence - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-6</other_id>
      <other_id>Y01-3-0012-6</other_id>
    </other_ids>
    <start_date>June 1992</start_date>
    <primary_completion_date>August 1993</primary_completion_date>
    <completion_date>October 1993</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000357</url>
  </study>
  <study rank="327218">
    <nct_id>NCT00000356</nct_id>
    <title>Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LAAM</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-5</other_id>
      <other_id>Y01-3-0012-5</other_id>
    </other_ids>
    <start_date>June 1991</start_date>
    <primary_completion_date>August 1992</primary_completion_date>
    <completion_date>October 1992</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000356</url>
  </study>
  <study rank="327219">
    <nct_id>NCT00000355</nct_id>
    <title>Effects of Buprenorphine and Naloxone in Opiate Addicts - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-4</other_id>
      <other_id>Y01-3-0012-4</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <primary_completion_date>January 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000355</url>
  </study>
  <study rank="327220">
    <nct_id>NCT00000354</nct_id>
    <title>Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lofexidine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-3</other_id>
      <other_id>Y01-3-0012-3</other_id>
    </other_ids>
    <start_date>July 1996</start_date>
    <primary_completion_date>September 1997</primary_completion_date>
    <completion_date>December 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000354</url>
  </study>
  <study rank="327221">
    <nct_id>NCT00000353</nct_id>
    <title>Trial of Buprenorphine/Naloxone for Opiate Dependence - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine/naloxone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>57 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-2</other_id>
      <other_id>Y01-3-0012-2</other_id>
    </other_ids>
    <start_date>October 1996</start_date>
    <primary_completion_date>September 1997</primary_completion_date>
    <completion_date>October 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 18, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000353</url>
  </study>
  <study rank="327222">
    <nct_id>NCT00000352</nct_id>
    <title>Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextromethorphan</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0012-1</other_id>
      <other_id>Y01-3-0012-1</other_id>
    </other_ids>
    <start_date>December 1996</start_date>
    <primary_completion_date>February 1998</primary_completion_date>
    <completion_date>April 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000352</url>
  </study>
  <study rank="327223">
    <nct_id>NCT00000351</nct_id>
    <title>Cognitive Correlates of Substance Abuse, Part 2 - 16</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amphetamine-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-3-0010-16</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000351</url>
  </study>
  <study rank="327224">
    <nct_id>NCT00000350</nct_id>
    <title>Effects of Stimulant Dependence on Human Striatal Dopamine System - 15</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amphetamine-Related Disorders</condition>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">radioactive substance</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-15</other_id>
      <other_id>Y01-3-0010-15</other_id>
    </other_ids>
    <start_date>March 1999</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000350</url>
  </study>
  <study rank="327225">
    <nct_id>NCT00000349</nct_id>
    <title>Infusion Laboratory: Protocol 5 (Flupenthixol) - 14</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, po</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual beh</outcome_measure>
      <outcome_measure>Evidence of change in neurophysiology and brain ac</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to coca</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challen</outcome_measure>
      <outcome_measure>Degree to which study medication influences change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-14</other_id>
      <other_id>Y01-3-0010-14</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000349</url>
  </study>
  <study rank="327226">
    <nct_id>NCT00000348</nct_id>
    <title>Infusion Laboratory: Protocol 4 (Dihydrexidine) - 13</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dihydrexidine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>Frequency of IV drug use and sexual risk behaviors</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, po</outcome_measure>
      <outcome_measure>Evidence of change in neurophysiology and brain ac</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to coca</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challen</outcome_measure>
      <outcome_measure>Degree to which study medication influences change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-13</other_id>
      <other_id>Y01-3-0010-13</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000348</url>
  </study>
  <study rank="327227">
    <nct_id>NCT00000347</nct_id>
    <title>Risperidone for Treatment of Cocaine Dependence in Outpatients - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-12</other_id>
      <other_id>Y01-3-0010-12</other_id>
    </other_ids>
    <start_date>July 1997</start_date>
    <primary_completion_date>August 1998</primary_completion_date>
    <completion_date>September 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000347</url>
  </study>
  <study rank="327228">
    <nct_id>NCT00000346</nct_id>
    <title>Cognitive Correlates of Substance Abuse - 11</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amphetamine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">counseling</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-11</other_id>
      <other_id>Y01-3-0010-11</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000346</url>
  </study>
  <study rank="327229">
    <nct_id>NCT00000345</nct_id>
    <title>Evaluation of Lofexidine for Treatment of Opiate Withdrawal - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lofexidine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opiate withdrawal</outcome_measure>
      <outcome_measure>Adverse effect measures</outcome_measure>
      <outcome_measure>Craving of opiates</outcome_measure>
      <outcome_measure>Liking of opiates</outcome_measure>
      <outcome_measure>Efficacy of lofexidine</outcome_measure>
      <outcome_measure>Euphoria</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-10</other_id>
      <other_id>Y01-3-0010-10</other_id>
    </other_ids>
    <start_date>April 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000345</url>
  </study>
  <study rank="327230">
    <nct_id>NCT00000344</nct_id>
    <title>Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine/naloxone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-9</other_id>
      <other_id>Y01-3-0010-9</other_id>
    </other_ids>
    <completion_date>August 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000344</url>
  </study>
  <study rank="327231">
    <nct_id>NCT00000343</nct_id>
    <title>Brain Changes in Stimulant Dependent Subjects - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">counseling</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-8</other_id>
      <other_id>Y01-3-0010-8</other_id>
    </other_ids>
    <start_date>April 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000343</url>
  </study>
  <study rank="327232">
    <nct_id>NCT00000342</nct_id>
    <title>Risperidone for the Treatment of Cocaine Dependence - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-7</other_id>
      <other_id>Y01-3-0010-7</other_id>
    </other_ids>
    <start_date>July 1996</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>September 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 16, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000342</url>
  </study>
  <study rank="327233">
    <nct_id>NCT00000341</nct_id>
    <title>Evaluation of Liquid vs. Tablet Buprenorphine - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective and observer rater physiological effects of bup</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-6</other_id>
      <other_id>Y01-3-0010-6</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <completion_date>August 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000341</url>
  </study>
  <study rank="327234">
    <nct_id>NCT00000340</nct_id>
    <title>Pemoline in the Treatment of Stimulant Dependence - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pemoline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Incidence of stimulant use</outcome_measure>
      <outcome_measure>Severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>ADHD symptom severity</outcome_measure>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>Frequency of IV drug use and sexual risk behaviors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-5</other_id>
      <other_id>Y01-3-0010-5</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000340</url>
  </study>
  <study rank="327235">
    <nct_id>NCT00000339</nct_id>
    <title>Infusion Laboratory: Protocol 3 (Risperidone) - 4</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evidence of change in neurotoxicity based on chore</outcome_measure>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, po</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual beh</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to coca</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challen</outcome_measure>
      <outcome_measure>Degree to which study medication influences change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-4</other_id>
      <other_id>Y01-3-0010-4</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000339</url>
  </study>
  <study rank="327236">
    <nct_id>NCT00000338</nct_id>
    <title>Infusion Laboratory: Protocol 2 (Lisuride) - 3</title>
    <acronym/>
    <status open="N">Unknown status</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lisuride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, po</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual beh</outcome_measure>
      <outcome_measure>Evidence of change in neurophysiology and brain ac</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to coca</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challen</outcome_measure>
      <outcome_measure>Degree to which study medication influences change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-3</other_id>
      <other_id>Y01-3-0010-3</other_id>
    </other_ids>
    <start_date>March 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 11, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000338</url>
  </study>
  <study rank="327237">
    <nct_id>NCT00000337</nct_id>
    <title>Infusion Laboratory: Protocol 1 - Selegeline - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Degree of drug craving</outcome_measure>
      <outcome_measure>History, incidence and amount of drug use</outcome_measure>
      <outcome_measure>Type and severity of stimulant withdrawal symptoms</outcome_measure>
      <outcome_measure>Population incidence of symptoms of depression, possible organic brain syndrome deficits</outcome_measure>
      <outcome_measure>Frequency and intensity of drug use and sexual behaviors at risk for HIV</outcome_measure>
      <outcome_measure>Evidence of change in neurophysiology and brain activity</outcome_measure>
      <outcome_measure>Evidence of change in subjective responses to cocaine challenge</outcome_measure>
      <outcome_measure>Clinical physiological response to cocaine challenge - especially adverse effects measures</outcome_measure>
      <outcome_measure>Degree to which study medication influences changes in #6, 7 &amp; 8 above (possible efficacy measure)</outcome_measure>
      <outcome_measure>Characterization of study population</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>31 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-2</other_id>
      <other_id>Y01-3-0010-2</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000337</url>
  </study>
  <study rank="327238">
    <nct_id>NCT00000336</nct_id>
    <title>Selegiline in Outpatient Treatment for Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Urine toxicology for cocaine</outcome_measure>
      <outcome_measure>Self reports of cocaine and other drug use and craving</outcome_measure>
      <outcome_measure>Evidence of change in neurotoxicity based on choreoathetoid movement assessments</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0010-1</other_id>
      <other_id>Y01-3-0010-1</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 16, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000336</url>
  </study>
  <study rank="327239">
    <nct_id>NCT00000335</nct_id>
    <title>Activity Monitoring Assessment of Opiate Withdrawal - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Morphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Withdrawal severity</outcome_measure>
      <outcome_measure>Activity</outcome_measure>
      <outcome_measure>Opiate secondary withdrawal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-4</other_id>
      <other_id>Y01-3-0009-4</other_id>
    </other_ids>
    <start_date>September 30, 1995</start_date>
    <primary_completion_date>March 20, 1996</primary_completion_date>
    <completion_date>May 20, 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 31, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000335</url>
  </study>
  <study rank="327240">
    <nct_id>NCT00000334</nct_id>
    <title>Comparison of Buprenorphine and Methadone - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Withdrawal severity</outcome_measure>
      <outcome_measure>Opiate agonist symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>23 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-3</other_id>
      <other_id>Y01-3-0009-3</other_id>
    </other_ids>
    <start_date>December 1, 2002</start_date>
    <primary_completion_date>November 1, 2004</primary_completion_date>
    <completion_date>January 15, 2005</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 31, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000334</url>
  </study>
  <study rank="327241">
    <nct_id>NCT00000333</nct_id>
    <title>Evaluation of Benztropine for Cocaine Craving - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Benztropine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stimulated and non-stimulated craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-2</other_id>
      <other_id>Y01-3-0009-2</other_id>
    </other_ids>
    <start_date>May 2001</start_date>
    <primary_completion_date>January 2003</primary_completion_date>
    <completion_date>April 2003</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>February 24, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000333</url>
  </study>
  <study rank="327242">
    <nct_id>NCT00000332</nct_id>
    <title>High Dose Nimodipine Treatment Adjunct - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nimodipine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stimulated and non-stimulated craving</outcome_measure>
      <outcome_measure>Stimulated and non-stimulated withdrawal</outcome_measure>
      <outcome_measure>Anxiety, depression</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Washington D.C. Veterans Affairs Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-3-0009-1</other_id>
      <other_id>Y01-3-0009-1</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <primary_completion_date>January 2000</primary_completion_date>
    <completion_date>April 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>February 24, 2017</last_update_posted>
    <locations>
      <location>Washington DC VA, Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000332</url>
  </study>
  <study rank="327243">
    <nct_id>NCT00000331</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Test Drug</intervention>
      <intervention type="Drug">Placebo Drug</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-6</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-6</other_id>
    </other_ids>
    <start_date>December 2002</start_date>
    <primary_completion_date>December 2002</primary_completion_date>
    <completion_date>December 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000331</url>
  </study>
  <study rank="327244">
    <nct_id>NCT00000330</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid-Related Disorders</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
      <outcome_measure>Drug/Money Preferences</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-5</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-5</other_id>
    </other_ids>
    <start_date>October 1999</start_date>
    <primary_completion_date>November 1999</primary_completion_date>
    <completion_date>November 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000330</url>
  </study>
  <study rank="327245">
    <nct_id>NCT00000329</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-1 - 4</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid-Related Disorders</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
      <outcome_measure>Drug/Money Preferences</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-4</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-4</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000329</url>
  </study>
  <study rank="327246">
    <nct_id>NCT00000328</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment III) - 3</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Opioid-Related Disorders</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Medication identification</outcome_measure>
      <outcome_measure>Addiction Severity Index (ASI) Composite Score Rating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-3</other_id>
      <other_id>1R01DA011160</other_id>
      <other_id>R01-11160-3</other_id>
    </other_ids>
    <start_date>July 1997</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>August 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000328</url>
  </study>
  <study rank="327247">
    <nct_id>NCT00000327</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Heroin Dependence</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Dosing schedule preferences</outcome_measure>
      <outcome_measure>Analog rating scale for dosing schedule effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>62 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-2</other_id>
      <other_id>R01DA011160</other_id>
      <other_id>R01-11160-2</other_id>
    </other_ids>
    <start_date>June 1997</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>August 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000327</url>
  </study>
  <study rank="327248">
    <nct_id>NCT00000326</nct_id>
    <title>Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment 1 - 1</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Heroin Dependence</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
      <outcome_measure>Drug effect characteristics</outcome_measure>
      <outcome_measure>Dose order estimate-nurse</outcome_measure>
      <outcome_measure>Dose order estimate-client</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-11160-1</other_id>
      <other_id>1R01DA011160</other_id>
      <other_id>R01-11160-1</other_id>
    </other_ids>
    <start_date>April 1997</start_date>
    <primary_completion_date>August 1997</primary_completion_date>
    <completion_date>August 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 4, 2017</last_update_posted>
    <locations>
      <location>University of Colorado Health Sciences Center, Denver, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000326</url>
  </study>
  <study rank="327249">
    <nct_id>NCT00000325</nct_id>
    <title>Psychostimulant Abuse - Novel Treatment Approaches - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Gonadorelin</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10757-1</other_id>
      <other_id>R01-10757-1</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000325</url>
  </study>
  <study rank="327250">
    <nct_id>NCT00000324</nct_id>
    <title>Tryptophan and Behavior Therapy for Cocaine Abuse - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tryptophan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Other drug use</outcome_measure>
      <outcome_measure>Psychosocial functioning</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10754-1</other_id>
      <other_id>R01-10754-1</other_id>
    </other_ids>
    <start_date>March 1997</start_date>
    <completion_date>April 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University School of Medicine, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000324</url>
  </study>
  <study rank="327251">
    <nct_id>NCT00000323</nct_id>
    <title>Therapeutic Potential of Kappa-Opioids Against Cocaine - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-10753-1</other_id>
      <other_id>R01-10753-1</other_id>
    </other_ids>
    <start_date>July 1996</start_date>
    <completion_date>December 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000323</url>
  </study>
  <study rank="327252">
    <nct_id>NCT00000322</nct_id>
    <title>Tyrosine for Methamphetamine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Amphetamine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Tyrosine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Functioning</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>89</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10739-1</other_id>
      <other_id>R01-10739-1</other_id>
    </other_ids>
    <start_date>April 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Haight Ashbury Free Clinics, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000322</url>
  </study>
  <study rank="327253">
    <nct_id>NCT00000321</nct_id>
    <title>Methamphetamine Abuse Treatment in Patients With AIDS - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Methamphetamine use</outcome_measure>
      <outcome_measure>Anxiety and Depression</outcome_measure>
      <outcome_measure>ASI Scales (7)</outcome_measure>
      <outcome_measure>AIDS medical care engagement</outcome_measure>
      <outcome_measure>High risk sexual behaviors</outcome_measure>
      <outcome_measure>Mood indicators</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Friends Research Institute, Inc.</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10643-1</other_id>
      <other_id>R01-10643-1</other_id>
    </other_ids>
    <start_date>October 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000321</url>
  </study>
  <study rank="327254">
    <nct_id>NCT00000320</nct_id>
    <title>Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine formulation: liquid vs. tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>blood level</outcome_measure>
      <outcome_measure>drug use</outcome_measure>
      <outcome_measure>craving</outcome_measure>
      <outcome_measure>withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-10068-1</other_id>
      <other_id>R01-10068-1</other_id>
    </other_ids>
    <start_date>October 1997</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000320</url>
  </study>
  <study rank="327255">
    <nct_id>NCT00000319</nct_id>
    <title>Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
      <outcome_measure>Opiate withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09803-2</other_id>
      <other_id>R01-09803-2</other_id>
    </other_ids>
    <start_date>June 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000319</url>
  </study>
  <study rank="327256">
    <nct_id>NCT00000318</nct_id>
    <title>Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09803-1</other_id>
      <other_id>R01-09803-1</other_id>
    </other_ids>
    <start_date>December 1994</start_date>
    <primary_completion_date>March 2004</primary_completion_date>
    <completion_date>August 2007</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000318</url>
  </study>
  <study rank="327257">
    <nct_id>NCT00000317</nct_id>
    <title>Early Phase II Trials for Cocaine Medication Development - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Behavioral">Relapse prevention counseling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Research Foundation for Mental Hygiene, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>#3124</other_id>
      <other_id>R01DA009582</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <primary_completion_date>July 1999</primary_completion_date>
    <completion_date>July 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 26, 2017</last_update_posted>
    <locations>
      <location>NYS Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000317</url>
  </study>
  <study rank="327258">
    <nct_id>NCT00000316</nct_id>
    <title>Human Dopamine Transported Imaging in Cocaine Abuse: 2 - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Psychological effects</outcome_measure>
      <outcome_measure>Effects of investigational drug</outcome_measure>
      <outcome_measure>Physiological changes in: heart rate and blood pre</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09482-2</other_id>
      <other_id>R01-09482-2</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000316</url>
  </study>
  <study rank="327259">
    <nct_id>NCT00000315</nct_id>
    <title>Human Dopamine Transported Imaging in Cocaine Abuse: 1 - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiological changes in: heart rate and blood pressure</outcome_measure>
      <outcome_measure>Subjective effects of cocaine inducements and withdrawal</outcome_measure>
      <outcome_measure>Psychological effects</outcome_measure>
      <outcome_measure>Effects of investigational drug</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09482-1</other_id>
      <other_id>R01-09482-1</other_id>
    </other_ids>
    <start_date>November 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000315</url>
  </study>
  <study rank="327260">
    <nct_id>NCT00000314</nct_id>
    <title>M-CPP and Fenfluramine in Cocaine Addicts - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">M-CPP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Hospitalization, arrests, jail, employment, psychiataric symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09468-3</other_id>
      <other_id>R01-09468-3</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 18, 2017</last_update_posted>
    <locations>
      <location>VA Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000314</url>
  </study>
  <study rank="327261">
    <nct_id>NCT00000313</nct_id>
    <title>Predictive Values of Serotonergic Alterations for Outcome - 2</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fenfluramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Neuroendocrine changes</outcome_measure>
      <outcome_measure>Psychological changes</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09468-2</other_id>
      <other_id>R01-09468-2</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>VA Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000313</url>
  </study>
  <study rank="327262">
    <nct_id>NCT00000312</nct_id>
    <title>Alterations in Serotonergic Functions in Cocaine Addicts - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">M-CPP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Neuroendocrine changes</outcome_measure>
      <outcome_measure>Psychological changes</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>US Department of Veterans Affairs</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09468-1</other_id>
      <other_id>R01-09468-1</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>VA Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000312</url>
  </study>
  <study rank="327263">
    <nct_id>NCT00000311</nct_id>
    <title>Combining Behavioral Treatment With Agonist Maintenance - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
      <intervention type="Drug">methadone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>168</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09413-1</other_id>
      <other_id>R01DA009413</other_id>
      <other_id>R01-09413-1</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <primary_completion_date>February 1999</primary_completion_date>
    <completion_date>February 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 17, 2018</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000311</url>
  </study>
  <study rank="327264">
    <nct_id>NCT00000310</nct_id>
    <title>Serotonin/Dopamine Antagonism of Cocaine Effect: 2 - 2</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Urine toxicology for cocaine</outcome_measure>
      <outcome_measure>Analog mood scales</outcome_measure>
      <outcome_measure>POMS</outcome_measure>
      <outcome_measure>EPS sx</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Boston Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09330-2</other_id>
      <other_id>R01-09330-2</other_id>
    </other_ids>
    <start_date>January 1996</start_date>
    <primary_completion_date>March 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 16, 2017</last_update_posted>
    <locations>
      <location>Brown University School of Medicine, Providence, Rhode Island, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000310</url>
  </study>
  <study rank="327265">
    <nct_id>NCT00000309</nct_id>
    <title>Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Analog mood scales</outcome_measure>
      <outcome_measure>POMS</outcome_measure>
      <outcome_measure>EPS sx</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Butler Hospital</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Boston Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09330-1</other_id>
      <other_id>R01DA009330</other_id>
      <other_id>R01-09330-1</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <primary_completion_date>January 2000</primary_completion_date>
    <completion_date>January 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 24, 2015</last_update_posted>
    <locations>
      <location>Brown University School of Medicine, Providence, Rhode Island, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000309</url>
  </study>
  <study rank="327266">
    <nct_id>NCT00000308</nct_id>
    <title>Dextroamphetamine-Cocaine Behavioral Intervention - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
      <intervention type="Drug">D-amphetamine</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Verifiable cocaine abstinence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-5</other_id>
      <other_id>P50-09262-5</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <primary_completion_date>September 2000</primary_completion_date>
    <completion_date>September 2000</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000308</url>
  </study>
  <study rank="327267">
    <nct_id>NCT00000307</nct_id>
    <title>Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Verified abstinence from cocaine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-4</other_id>
      <other_id>P50-09262-4</other_id>
    </other_ids>
    <start_date>April 2003</start_date>
    <primary_completion_date>April 2007</primary_completion_date>
    <completion_date>April 2007</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000307</url>
  </study>
  <study rank="327268">
    <nct_id>NCT00000306</nct_id>
    <title>Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Medication compliance</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Addiction severity</outcome_measure>
      <outcome_measure>Mood indicators</outcome_measure>
      <outcome_measure>Psychiatric interview</outcome_measure>
      <outcome_measure>Effectiveness measures including psycho-social variables, side effects, and self-reported measures.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-3</other_id>
      <other_id>P50-09262-3</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <completion_date>September 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000306</url>
  </study>
  <study rank="327269">
    <nct_id>NCT00000305</nct_id>
    <title>Amphetamine Cocaine Interaction Study - 2</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>The University of Texas Health Science Center, Houston</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-2</other_id>
      <other_id>P50DA009262</other_id>
      <other_id>P50-09262-2</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 18, 2012</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000305</url>
  </study>
  <study rank="327270">
    <nct_id>NCT00000304</nct_id>
    <title>Dextroamphetamine as an Adjunct in Cocaine Treatment - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dextroamphetamine</intervention>
      <intervention type="Drug">D-Amphetamine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>verifiable cocaine abstinence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Texas</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09262-1</other_id>
      <other_id>P50-09262-1</other_id>
    </other_ids>
    <start_date>August 1997</start_date>
    <primary_completion_date>August 2001</primary_completion_date>
    <completion_date>August 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000304</url>
  </study>
  <study rank="327271">
    <nct_id>NCT00000303</nct_id>
    <title>Rapid Evaluation of Baclofen for Treatment of Cocaine Abuse/Dependence - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Baclofen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Psychosocial progress</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-6</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-6</other_id>
    </other_ids>
    <start_date>October 1997</start_date>
    <primary_completion_date>May 1999</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000303</url>
  </study>
  <study rank="327272">
    <nct_id>NCT00000302</nct_id>
    <title>Study Comparing Liquid and Tablet Buprenorphine Formulations - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Drug craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-5</other_id>
      <other_id>P50-09260-5</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 7, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000302</url>
  </study>
  <study rank="327273">
    <nct_id>NCT00000301</nct_id>
    <title>Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amantadine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Psychosocial progress</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-4</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-4</other_id>
    </other_ids>
    <start_date>March 1996</start_date>
    <primary_completion_date>June 1998</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000301</url>
  </study>
  <study rank="327274">
    <nct_id>NCT00000300</nct_id>
    <title>Feasibility Study of Take-Home LAAM Medication - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LAAM</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Increased prosocial behaviors</outcome_measure>
      <outcome_measure>Decreased frequency of HIV related behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-3</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-3</other_id>
    </other_ids>
    <start_date>March 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 1, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000300</url>
  </study>
  <study rank="327275">
    <nct_id>NCT00000299</nct_id>
    <title>Rapid Opiate Detoxification and Naltrexone Induction Using Buprenorphine - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opiate craving</outcome_measure>
      <outcome_measure>Opiate withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-2</other_id>
      <other_id>P50DA009260</other_id>
      <other_id>P50-09260-2</other_id>
    </other_ids>
    <start_date>October 2008</start_date>
    <primary_completion_date>November 2009</primary_completion_date>
    <completion_date>November 2009</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 29, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000299</url>
  </study>
  <study rank="327276">
    <nct_id>NCT00000298</nct_id>
    <title>Buprenorphine Combination Tablet Feasibility - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine/naloxone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09260-1</other_id>
      <other_id>P50-09260-1</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000298</url>
  </study>
  <study rank="327277">
    <nct_id>NCT00000297</nct_id>
    <title>Effects of Labetalol on Nicotine Administration in Humans - 14</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Labetalol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiologic measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-14</other_id>
      <other_id>P50-09259-14</other_id>
    </other_ids>
    <start_date>October 1998</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000297</url>
  </study>
  <study rank="327278">
    <nct_id>NCT00000296</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (4) - 13</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cotinine fumarate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Behavioral</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-13</other_id>
      <other_id>P50-09259-13</other_id>
    </other_ids>
    <start_date>November 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000296</url>
  </study>
  <study rank="327279">
    <nct_id>NCT00000295</nct_id>
    <title>Progesterone Treatment in Female Smokers - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Micronized Progesterone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Biochemical</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-12</other_id>
      <other_id>P50-09259-12</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000295</url>
  </study>
  <study rank="327280">
    <nct_id>NCT00000294</nct_id>
    <title>Effects of Carvedilol on Cocaine Use in Humans - 11</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carvedilol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiologic measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-11</other_id>
      <other_id>P50-09259-11</other_id>
    </other_ids>
    <start_date>September 1998</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000294</url>
  </study>
  <study rank="327281">
    <nct_id>NCT00000293</nct_id>
    <title>Effect of Nefazodone on Relapse in Females With Cocaine Abuse - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nefazodone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Primary drug use</outcome_measure>
      <outcome_measure>Depression (secondary)</outcome_measure>
      <outcome_measure>Relapse</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-10</other_id>
      <other_id>P50-09259-10</other_id>
    </other_ids>
    <start_date>January 1999</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000293</url>
  </study>
  <study rank="327282">
    <nct_id>NCT00000292</nct_id>
    <title>Acute Withdrawal From Smoked Cocaine - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance Withdrawal Syndrome</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiological measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-9</other_id>
      <other_id>P50-09259-9</other_id>
    </other_ids>
    <start_date>April 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000292</url>
  </study>
  <study rank="327283">
    <nct_id>NCT00000291</nct_id>
    <title>Effects of Labetalol on Human Cocaine Use - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Labetalol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective</outcome_measure>
      <outcome_measure>Physiological measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-8</other_id>
      <other_id>P50-09259-8</other_id>
    </other_ids>
    <start_date>October 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000291</url>
  </study>
  <study rank="327284">
    <nct_id>NCT00000290</nct_id>
    <title>Stress Hormones and Human Cocaine Use - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiological measures</outcome_measure>
      <outcome_measure>Biochemical</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-7</other_id>
      <other_id>P50-09259-7</other_id>
    </other_ids>
    <start_date>May 1997</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000290</url>
  </study>
  <study rank="327285">
    <nct_id>NCT00000289</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (3) - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ondansetron</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Performance effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-6</other_id>
      <other_id>P50-09259-6</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000289</url>
  </study>
  <study rank="327286">
    <nct_id>NCT00000288</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (2) - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cotinine fumarate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Behavioral</outcome_measure>
      <outcome_measure>Subjective</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-5</other_id>
      <other_id>P50-09259-5</other_id>
    </other_ids>
    <start_date>December 1995</start_date>
    <completion_date>December 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000288</url>
  </study>
  <study rank="327287">
    <nct_id>NCT00000287</nct_id>
    <title>Relapse Patterns in Female Cocaine Users - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-09259-4</other_id>
      <other_id>P50-09259-4</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <primary_completion_date>December 2001</primary_completion_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000287</url>
  </study>
  <study rank="327288">
    <nct_id>NCT00000286</nct_id>
    <title>Effects of Nefazodone on Treatment of Female Cocaine Abusers - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nefazodone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Life functioning</outcome_measure>
      <outcome_measure>HIV risk behaviors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-3</other_id>
      <other_id>P50-09259-3</other_id>
    </other_ids>
    <start_date>December 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000286</url>
  </study>
  <study rank="327289">
    <nct_id>NCT00000285</nct_id>
    <title>Effects of Phenytoin on Cocaine Use in Humans - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Phenytoin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Behavioral</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-2</other_id>
      <other_id>P50-09259-2</other_id>
    </other_ids>
    <start_date>May 1996</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000285</url>
  </study>
  <study rank="327290">
    <nct_id>NCT00000284</nct_id>
    <title>Role of Metabolites in Nicotine Dependence (1) - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tobacco Use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cotinine fumarate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subjective effects</outcome_measure>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Performance effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09259-1</other_id>
      <other_id>P50-09259-1</other_id>
    </other_ids>
    <start_date>February 1995</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000284</url>
  </study>
  <study rank="327291">
    <nct_id>NCT00000282</nct_id>
    <title>Pemoline for Cocaine Abuse - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pemoline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-7</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-7</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>December 15, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000282</url>
  </study>
  <study rank="327292">
    <nct_id>NCT00000281</nct_id>
    <title>Pharmacotherapy for Schizophrenic Drug Users - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
      <condition>Shcizophrenia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Amantadine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Psychological symptoms</outcome_measure>
      <outcome_measure>Schizophrenic symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-6</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-6</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>December 15, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000281</url>
  </study>
  <study rank="327293">
    <nct_id>NCT00000280</nct_id>
    <title>Glutaminergic Agents for Cocaine Abuse - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nimodipine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-5</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-5</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>April 25, 2017</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000280</url>
  </study>
  <study rank="327294">
    <nct_id>NCT00000279</nct_id>
    <title>Novel Medications for Opiate Detoxification - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clonidine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Withdrawal severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-4</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-4</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000279</url>
  </study>
  <study rank="327295">
    <nct_id>NCT00000278</nct_id>
    <title>Disulfiram for Cocaine-Alcohol Abuse - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Disulfiram</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Cocaine effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-3</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-3</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000278</url>
  </study>
  <study rank="327296">
    <nct_id>NCT00000277</nct_id>
    <title>Mazindol for Cocaine Abuse - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mazindol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-2</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-2</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000277</url>
  </study>
  <study rank="327297">
    <nct_id>NCT00000276</nct_id>
    <title>Dopamine Reuptake Inhibitors of Cocaine Abuse - 1</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bupropion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Cocaine effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>VA Connecticut Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09250-1</other_id>
      <other_id>P50DA009250</other_id>
      <other_id>P50-09250-1</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>August 1999</primary_completion_date>
    <completion_date>August 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000276</url>
  </study>
  <study rank="327298">
    <nct_id>NCT00000275</nct_id>
    <title>Cocaine Abuse and ADHD - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>ADHD symptoms</outcome_measure>
      <outcome_measure>Improvement in functioning</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-10</other_id>
      <other_id>P50-09236-10</other_id>
    </other_ids>
    <start_date>November 1996</start_date>
    <completion_date>March 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000275</url>
  </study>
  <study rank="327299">
    <nct_id>NCT00000274</nct_id>
    <title>Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-9</other_id>
      <other_id>P50-09236-9</other_id>
    </other_ids>
    <start_date>March 1997</start_date>
    <completion_date>May 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000274</url>
  </study>
  <study rank="327300">
    <nct_id>NCT00000273</nct_id>
    <title>A Laboratory Model for Heroin Abuse Medications - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heroin Dependence</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">opiates</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Amount drug self-administered</outcome_measure>
      <outcome_measure>Subjective responses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>#4857/5982R</other_id>
      <other_id>5P50DA009236-18</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <primary_completion_date>November 2005</primary_completion_date>
    <completion_date>November 2005</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 5, 2017</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000273</url>
  </study>
  <study rank="327301">
    <nct_id>NCT00000271</nct_id>
    <title>New Approaches to Cocaine Abuse Medications (A) - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine Use</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>111</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>3881</other_id>
      <other_id>5P50DA009236-18</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <primary_completion_date>October 2002</primary_completion_date>
    <completion_date>October 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 5, 2017</last_update_posted>
    <locations>
      <location>Research Foundation for Mental Hygiene, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000271</url>
  </study>
  <study rank="327302">
    <nct_id>NCT00000270</nct_id>
    <title>Brain Imaging: Cocaine Effects &amp; Medication Development - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Absolute change in rCBF at 5 &amp; 15 minutes (Xe)</outcome_measure>
      <outcome_measure>Relative change in rCBF at 5, 19, &amp; 33 minutes (O15)</outcome_measure>
      <outcome_measure>Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-5</other_id>
      <other_id>5P50DA009236-18</other_id>
      <other_id>P50-09236-5</other_id>
    </other_ids>
    <start_date>December 30, 1995</start_date>
    <primary_completion_date>December 30, 1995</primary_completion_date>
    <completion_date>December 30, 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 2, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000270</url>
  </study>
  <study rank="327303">
    <nct_id>NCT00000269</nct_id>
    <title>Pergolide Treatment for Substance Abusers - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pergolide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Improvement in functioning</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-4</other_id>
      <other_id>P50-09236-4</other_id>
    </other_ids>
    <start_date>October 1995</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000269</url>
  </study>
  <study rank="327304">
    <nct_id>NCT00000268</nct_id>
    <title>Cocaine Abuse and Attention Deficit Disorder - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bupropion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>ADHD symptoms</outcome_measure>
      <outcome_measure>Improvement in functioning</outcome_measure>
      <outcome_measure>Tolerability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-3</other_id>
      <other_id>P50-09236-3</other_id>
    </other_ids>
    <start_date>May 1995</start_date>
    <completion_date>November 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000268</url>
  </study>
  <study rank="327305">
    <nct_id>NCT00000267</nct_id>
    <title>Risperidone Treatment in Dually-Diagnosed Individuals - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Risperidone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-2</other_id>
      <other_id>P50-09236-2</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000267</url>
  </study>
  <study rank="327306">
    <nct_id>NCT00000266</nct_id>
    <title>Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Psychiatric symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>New York State Psychiatric Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-09236-1</other_id>
      <other_id>P50-09236-1</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000266</url>
  </study>
  <study rank="327307">
    <nct_id>NCT00000265</nct_id>
    <title>Subjective Effects of Nitrous Oxide in Dental Patients - 17</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Anxiety scale</outcome_measure>
      <outcome_measure>Mood scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-17</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-17</other_id>
    </other_ids>
    <start_date>July 1997</start_date>
    <primary_completion_date>January 2002</primary_completion_date>
    <completion_date>January 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000265</url>
  </study>
  <study rank="327308">
    <nct_id>NCT00000264</nct_id>
    <title>Subjective/Psychomotor/ Effects of Combined Alcohol &amp; Nitrous Oxide - 16</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Other">0.35 g/Kg ethanol</intervention>
      <intervention type="Other">0.7 g/Kg ethanol</intervention>
      <intervention type="Other">0 g/Kg ethanol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-16</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-16</other_id>
    </other_ids>
    <start_date>September 1997</start_date>
    <primary_completion_date>October 1999</primary_completion_date>
    <completion_date>October 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000264</url>
  </study>
  <study rank="327309">
    <nct_id>NCT00000263</nct_id>
    <title>Effects of Combined Alcohol and Nitrous Oxide Intake - 15</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Other">0.25 g/Kg ethanol</intervention>
      <intervention type="Other">0.5 g/KG ethanol</intervention>
      <intervention type="Other">0 g/Kg ethanol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity, pain bothersomeness</outcome_measure>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-15</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-15</other_id>
    </other_ids>
    <start_date>January 1997</start_date>
    <primary_completion_date>October 1998</primary_completion_date>
    <completion_date>October 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000263</url>
  </study>
  <study rank="327310">
    <nct_id>NCT00000262</nct_id>
    <title>Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Drug">0.4% Sevoflurane</intervention>
      <intervention type="Drug">0.2% sevoflurane</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity, pain bothersomeness</outcome_measure>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-14</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-14</other_id>
    </other_ids>
    <start_date>November 1996</start_date>
    <primary_completion_date>February 1999</primary_completion_date>
    <completion_date>February 1999</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000262</url>
  </study>
  <study rank="327311">
    <nct_id>NCT00000261</nct_id>
    <title>Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">0.2% sevoflurane</intervention>
      <intervention type="Drug">0.4% sevoflurane</intervention>
      <intervention type="Drug">0.6% sevoflurane</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Choice of drug vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-13</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-13</other_id>
    </other_ids>
    <start_date>November 1997</start_date>
    <primary_completion_date>October 1998</primary_completion_date>
    <completion_date>October 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000261</url>
  </study>
  <study rank="327312">
    <nct_id>NCT00000260</nct_id>
    <title>Effects of Behavioral Contingencies on Effects of Nitrous Oxide - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitrous oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mood</outcome_measure>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>NIDA-08391-12</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-12</other_id>
    </other_ids>
    <start_date>June 1997</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000260</url>
  </study>
  <study rank="327313">
    <nct_id>NCT00000259</nct_id>
    <title>Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">15 % Nitrous oxide</intervention>
      <intervention type="Drug">0.3 % Sevoflurane</intervention>
      <intervention type="Drug">30% Nitrous oxide</intervention>
      <intervention type="Drug">0.6% Sevoflurane</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity</outcome_measure>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>39 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-11</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-11</other_id>
    </other_ids>
    <start_date>August 1996</start_date>
    <primary_completion_date>November 1997</primary_completion_date>
    <completion_date>November 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000259</url>
  </study>
  <study rank="327314">
    <nct_id>NCT00000258</nct_id>
    <title>Role of Instructions in Nitrous Oxide Effects and Choice - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitrous oxide 10% &amp; placebo</intervention>
      <intervention type="Drug">Nitrous oxide 20% &amp; placebo</intervention>
      <intervention type="Drug">Nitrous oxide 30% &amp; placebo</intervention>
      <intervention type="Drug">Nitrous oxide 40% and placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>32 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-10</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-10</other_id>
    </other_ids>
    <start_date>April 1996</start_date>
    <primary_completion_date>November 1997</primary_completion_date>
    <completion_date>November 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000258</url>
  </study>
  <study rank="327315">
    <nct_id>NCT00000257</nct_id>
    <title>Effects of Alcohol History on Effects of Nitrous Oxide - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0% N2O and 10% N2O</intervention>
      <intervention type="Drug">0% N2O and 20% N2O</intervention>
      <intervention type="Drug">0% N2O and 30% N2O</intervention>
      <intervention type="Drug">0% N2O and 40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-9</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-9</other_id>
    </other_ids>
    <start_date>September 1995</start_date>
    <primary_completion_date>April 1997</primary_completion_date>
    <completion_date>April 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000257</url>
  </study>
  <study rank="327316">
    <nct_id>NCT00000256</nct_id>
    <title>Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
      <intervention type="Drug">60% N2O</intervention>
      <intervention type="Drug">80% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of nitrous oxide vs placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>34 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-8</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-8</other_id>
    </other_ids>
    <start_date>August 1995</start_date>
    <primary_completion_date>November 1996</primary_completion_date>
    <completion_date>November 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000256</url>
  </study>
  <study rank="327317">
    <nct_id>NCT00000255</nct_id>
    <title>Differential Acute Tolerance Development to Effects of Nitrous Oxide - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitrous oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity, pain bothersomeness</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-7</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-7</other_id>
    </other_ids>
    <start_date>April 1995</start_date>
    <primary_completion_date>May 1996</primary_completion_date>
    <completion_date>May 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000255</url>
  </study>
  <study rank="327318">
    <nct_id>NCT00000254</nct_id>
    <title>Isoflurane at Subanesthetic Concentrations - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">40% Nitrous oxide</intervention>
      <intervention type="Other">Sham comparator</intervention>
      <intervention type="Drug">0.2% isoflurane</intervention>
      <intervention type="Drug">0.4% isoflurane</intervention>
      <intervention type="Drug">0.6% isoflurane</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>34 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-6</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-6</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <primary_completion_date>September 1995</primary_completion_date>
    <completion_date>September 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000254</url>
  </study>
  <study rank="327319">
    <nct_id>NCT00000253</nct_id>
    <title>Effects of Nitrous Oxide: A Dose-Response Analysis - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">10% N2O</intervention>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Choice of N2O vs. placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-5</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-5</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <primary_completion_date>March 1996</primary_completion_date>
    <completion_date>March 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000253</url>
  </study>
  <study rank="327320">
    <nct_id>NCT00000252</nct_id>
    <title>Lack of Acute Tolerance Development to Effects of Nitrous Oxide - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0% N2O</intervention>
      <intervention type="Drug">10% N2O</intervention>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Psychomotor performance</outcome_measure>
      <outcome_measure>Cognitive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>29 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-4</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-4</other_id>
    </other_ids>
    <start_date>June 1994</start_date>
    <primary_completion_date>June 1996</primary_completion_date>
    <completion_date>June 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000252</url>
  </study>
  <study rank="327321">
    <nct_id>NCT00000251</nct_id>
    <title>Effects of Subanesthetic Concentrations of Isoflurane/Nitrous Oxide - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">0.2% isoflurane</intervention>
      <intervention type="Drug">0.4% isoflurane</intervention>
      <intervention type="Other">100% oxygen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Logical reasoning test</outcome_measure>
      <outcome_measure>Free recall memory test</outcome_measure>
      <outcome_measure>Auditory reaction time</outcome_measure>
      <outcome_measure>Digit symbol substitution test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>32 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-3</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-3</other_id>
    </other_ids>
    <start_date>April 1994</start_date>
    <primary_completion_date>January 1996</primary_completion_date>
    <completion_date>January 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>December 2, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000251</url>
  </study>
  <study rank="327322">
    <nct_id>NCT00000250</nct_id>
    <title>Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">0% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Subject's choice of intervention</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>32 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-2</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-2</other_id>
    </other_ids>
    <start_date>December 1993</start_date>
    <primary_completion_date>May 1995</primary_completion_date>
    <completion_date>May 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000250</url>
  </study>
  <study rank="327323">
    <nct_id>NCT00000249</nct_id>
    <title>Effects of Subanesthetic Concentrations of Nitrous Oxide - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">20% N2O</intervention>
      <intervention type="Drug">30% N2O</intervention>
      <intervention type="Drug">40% N2O</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain intensity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>37 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08391-1</other_id>
      <other_id>R01DA008391</other_id>
      <other_id>R01-08391-1</other_id>
    </other_ids>
    <start_date>September 1993</start_date>
    <primary_completion_date>June 1995</primary_completion_date>
    <completion_date>June 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Chicago, Anesthesia &amp; Critical Care, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000249</url>
  </study>
  <study rank="327324">
    <nct_id>NCT00000248</nct_id>
    <title>Dose Response Trial of Pergolide for Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pergolide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine withdrawal</outcome_measure>
      <outcome_measure>Compliance</outcome_measure>
      <outcome_measure>Effectiveness of medication for global improvements</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of South Carolina</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08355-1</other_id>
      <other_id>R01DA008355</other_id>
      <other_id>R01-08355-1</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 16, 2018</last_update_posted>
    <locations>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000248</url>
  </study>
  <study rank="327325">
    <nct_id>NCT00000246</nct_id>
    <title>Rapid Benzodiazepine Detoxification Using Flumazenil - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flumazenil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Benzodiazepine withdrawal severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08265-1</other_id>
      <other_id>R01DA008265</other_id>
      <other_id>R01-08265-1</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>December 1994</primary_completion_date>
    <completion_date>December 1994</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>September 8, 2016</last_update_posted>
    <locations>
      <location>Yale University, Psychiatry, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000246</url>
  </study>
  <study rank="327326">
    <nct_id>NCT00000245</nct_id>
    <title>Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Mood indicators</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Friends Research Institute, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08082-1</other_id>
      <other_id>R01-08082-1</other_id>
    </other_ids>
    <start_date>May 1994</start_date>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000245</url>
  </study>
  <study rank="327327">
    <nct_id>NCT00000244</nct_id>
    <title>Effects of Dynorphin 1-13 on Heroin Addiction - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance Withdrawal Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dynorphin 1 - 13</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Craving scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08067-1</other_id>
      <other_id>R01DA008067</other_id>
      <other_id>R01-08067-1</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <primary_completion_date>March 1997</primary_completion_date>
    <completion_date>March 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 27, 2015</last_update_posted>
    <locations>
      <location>U of Minnesota School of Medicine, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000244</url>
  </study>
  <study rank="327328">
    <nct_id>NCT00000243</nct_id>
    <title>Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiological effects</outcome_measure>
      <outcome_measure>Analog rating scale for drug effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-08045-1</other_id>
      <other_id>R01-08045-1</other_id>
      <other_id>DPMC</other_id>
    </other_ids>
    <start_date>September 2002</start_date>
    <completion_date>January 2004</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000243</url>
  </study>
  <study rank="327329">
    <nct_id>NCT00000242</nct_id>
    <title>Carbamazepine Treatment of Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity addiction</outcome_measure>
      <outcome_measure>Amount of drug use</outcome_measure>
      <outcome_measure>Affective stability</outcome_measure>
      <outcome_measure>Medication compliance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of South Carolina</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-07761-1</other_id>
      <other_id>R29DA007761</other_id>
      <other_id>R29-07761-1</other_id>
    </other_ids>
    <start_date>October 1, 1992</start_date>
    <primary_completion_date>January 25, 1997</primary_completion_date>
    <completion_date>January 25, 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>April 7, 2017</last_update_posted>
    <locations>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000242</url>
  </study>
  <study rank="327330">
    <nct_id>NCT00000241</nct_id>
    <title>Flupenthixol Decanoate in Methamphetamine Smoking - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Flupenthixol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Methamphetamine use</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Friends Research Institute, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-07200-1</other_id>
      <other_id>R01-07200-1</other_id>
    </other_ids>
    <start_date>February 1994</start_date>
    <completion_date>May 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000241</url>
  </study>
  <study rank="327331">
    <nct_id>NCT00000240</nct_id>
    <title>Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
      <outcome_measure>Opioid dependence and psychiatric status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>23 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-22</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-22</other_id>
    </other_ids>
    <start_date>April 1999</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 3, 2015</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000240</url>
  </study>
  <study rank="327332">
    <nct_id>NCT00000239</nct_id>
    <title>Buprenorphine Pharmacology Related to Addiction Treatment - 21</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Opiate withdrawal</outcome_measure>
      <outcome_measure>Physiological changes in: pupil diameter, blood pressure, heart rate, respiration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-21</other_id>
      <other_id>R01-06969-21</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000239</url>
  </study>
  <study rank="327333">
    <nct_id>NCT00000238</nct_id>
    <title>Temporal Discounting Delayed Outcomes on Opioid-Dependent Outpatients - 20</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Money choice</outcome_measure>
      <outcome_measure>Heroin craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-20</other_id>
      <other_id>R01-06969-20</other_id>
    </other_ids>
    <start_date>August 1997</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 20, 2008</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000238</url>
  </study>
  <study rank="327334">
    <nct_id>NCT00000237</nct_id>
    <title>Buprenorphine Detoxification - BBDVI - 19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
      <outcome_measure>Opioid dependence and psychiatric status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-19</other_id>
      <other_id>R01-06969-19</other_id>
    </other_ids>
    <start_date>May 1997</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000237</url>
  </study>
  <study rank="327335">
    <nct_id>NCT00000236</nct_id>
    <title>Buprenorphine Pharmacology Related to Addiction Treatment - 18</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine/naloxone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Opiate withdrawal</outcome_measure>
      <outcome_measure>Psychological changes in: pupil diameter, blood pressure, heart rate, respiration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-18</other_id>
      <other_id>R01-06969-18</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000236</url>
  </study>
  <study rank="327336">
    <nct_id>NCT00000235</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase XII - 17</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-17</other_id>
      <other_id>R01-06969-17</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000235</url>
  </study>
  <study rank="327337">
    <nct_id>NCT00000234</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase XI - 16</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-16</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-16</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000234</url>
  </study>
  <study rank="327338">
    <nct_id>NCT00000233</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase X - 15</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Drug effect characteristics: ARCI</outcome_measure>
      <outcome_measure>Money choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>34 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-15</other_id>
      <other_id>R01-06969-15</other_id>
    </other_ids>
    <start_date>May 1993</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000233</url>
  </study>
  <study rank="327339">
    <nct_id>NCT00000232</nct_id>
    <title>Alternate Day Buprenorphine Administration, Phase IX - 14</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>22 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-14</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-14</other_id>
    </other_ids>
    <start_date>March 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000232</url>
  </study>
  <study rank="327340">
    <nct_id>NCT00000231</nct_id>
    <title>Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
      <outcome_measure>Naltrexone consumption</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-13</other_id>
      <other_id>R01-06969-13</other_id>
    </other_ids>
    <start_date>February 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000231</url>
  </study>
  <study rank="327341">
    <nct_id>NCT00000230</nct_id>
    <title>Buprenorphine Detoxification With Two Types of Treatment. BBD III - 12</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-12</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-12</other_id>
    </other_ids>
    <start_date>January 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000230</url>
  </study>
  <study rank="327342">
    <nct_id>NCT00000229</nct_id>
    <title>Buprenorphine Detox With Two Types of Treatment. BBD II - 11</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-11</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-11</other_id>
    </other_ids>
    <start_date>October 1995</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000229</url>
  </study>
  <study rank="327343">
    <nct_id>NCT00000228</nct_id>
    <title>Buprenorphine Detox With Two Types of Treatment. BBD I - 10</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Weeks abstinent</outcome_measure>
      <outcome_measure>Weeks continuous abstinence</outcome_measure>
      <outcome_measure>Overall treatment outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-10</other_id>
      <other_id>R01-06969-10</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000228</url>
  </study>
  <study rank="327344">
    <nct_id>NCT00000227</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase VIII - 9</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose choice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-9</other_id>
      <other_id>R01DA006969</other_id>
      <other_id>R01-06969-9</other_id>
    </other_ids>
    <start_date>August 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000227</url>
  </study>
  <study rank="327345">
    <nct_id>NCT00000226</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase VII - 8</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>48 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-8</other_id>
      <other_id>R01-06969-8</other_id>
    </other_ids>
    <start_date>November 1994</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000226</url>
  </study>
  <study rank="327346">
    <nct_id>NCT00000225</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase VI - 7</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-7</other_id>
      <other_id>R01-06969-7</other_id>
    </other_ids>
    <start_date>December 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000225</url>
  </study>
  <study rank="327347">
    <nct_id>NCT00000224</nct_id>
    <title>Alternate-Day Buprenorphine. Phase V - 6</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Drug effect characteristics: ARCI</outcome_measure>
      <outcome_measure>Physiological changes in: pupil diameter</outcome_measure>
      <outcome_measure>Physiological changes in: blood pressure</outcome_measure>
      <outcome_measure>Physiological changes in: heart rate</outcome_measure>
      <outcome_measure>Physiological changes in: respiration</outcome_measure>
      <outcome_measure>Physiological changes in: bup plasma levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-6</other_id>
      <other_id>R01-06969-6</other_id>
    </other_ids>
    <start_date>February 1993</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000224</url>
  </study>
  <study rank="327348">
    <nct_id>NCT00000223</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase IV - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-5</other_id>
      <other_id>R01-06969-5</other_id>
    </other_ids>
    <start_date>June 1993</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000223</url>
  </study>
  <study rank="327349">
    <nct_id>NCT00000222</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase II - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>28 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-4</other_id>
      <other_id>R01-06969-4</other_id>
    </other_ids>
    <start_date>July 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000222</url>
  </study>
  <study rank="327350">
    <nct_id>NCT00000221</nct_id>
    <title>Alternate-Day Buprenorphine Administration. Phase I - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Opioid agonist effects</outcome_measure>
      <outcome_measure>Dose identification</outcome_measure>
      <outcome_measure>Pupil diameter</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>28 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-3</other_id>
      <other_id>R01-06969-3</other_id>
    </other_ids>
    <start_date>April 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000221</url>
  </study>
  <study rank="327351">
    <nct_id>NCT00000220</nct_id>
    <title>Gradual Vs. Rapid Buprenorphine Detoxification - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Observed withdrawal rating</outcome_measure>
      <outcome_measure>Opioid agonist rating</outcome_measure>
      <outcome_measure>Opioid antagonist rating</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Vermont</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>33 Years</min_age>
    <max_age>43 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-2</other_id>
      <other_id>R01-06969-2</other_id>
    </other_ids>
    <start_date>June 1991</start_date>
    <completion_date>July 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 24, 2005</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000220</url>
  </study>
  <study rank="327352">
    <nct_id>NCT00000219</nct_id>
    <title>Buprenorphine Dose Alteration Study - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Opioid withdrawal</outcome_measure>
      <outcome_measure>Subjective dose estimate</outcome_measure>
      <outcome_measure>Drug effect characteristics: ARCI</outcome_measure>
      <outcome_measure>Physiological changes in: pupil diameter</outcome_measure>
      <outcome_measure>Physiological changes in: blood pressure</outcome_measure>
      <outcome_measure>Physiological changes in: heart rate</outcome_measure>
      <outcome_measure>Physiological changes in: respiration</outcome_measure>
      <outcome_measure>Physiological changes in: skin temperature</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Vermont</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>19 Years</min_age>
    <max_age>41 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06969-1</other_id>
      <other_id>R18DA006969</other_id>
      <other_id>R01-06969-1</other_id>
    </other_ids>
    <start_date>December 1991</start_date>
    <completion_date>July 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>Treatment Research Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000219</url>
  </study>
  <study rank="327353">
    <nct_id>NCT00000218</nct_id>
    <title>Pharmacotherapy and Intensive Treatment - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity addiction</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Depression, anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>VA Office of Research and Development</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06954-2</other_id>
      <other_id>R18-06954-2</other_id>
    </other_ids>
    <completion_date>June 2005</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Kansas, Kansas City, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000218</url>
  </study>
  <study rank="327354">
    <nct_id>NCT00000217</nct_id>
    <title>Pharmacotherapy and Intensive Treatment of Drug Abuse - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Effectiveness of medication</outcome_measure>
      <outcome_measure>Level of pharm</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Depression, anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Kansas</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>US Department of Veterans Affairs</collaborator>
      <collaborator>University of Kansas Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06954-1</other_id>
      <other_id>R18DA006954</other_id>
      <other_id>R18-06954-1</other_id>
    </other_ids>
    <start_date>September 1990</start_date>
    <primary_completion_date>October 1996</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>April 16, 2015</last_update_posted>
    <locations>
      <location>University of Kansas, Kansas City, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000217</url>
  </study>
  <study rank="327355">
    <nct_id>NCT00000216</nct_id>
    <title>Buprenorphine Maintenance for Cocaine Abusing Opioid Addicts - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Opioid-Related Disorders</condition>
      <condition>Substance-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opioid and cocaine use</outcome_measure>
      <outcome_measure>Social and psychological functioning</outcome_measure>
      <outcome_measure>AIDS risk behavior</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Yale University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06266-1</other_id>
      <other_id>R01-06266-1</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>APT Residential Services Division, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000216</url>
  </study>
  <study rank="327356">
    <nct_id>NCT00000215</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pergolide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Direct cocaine effects (cardio, subjective)</outcome_measure>
      <outcome_measure>Interaction of cocaine/pergolide on cardio</outcome_measure>
      <outcome_measure>Interaction of coc/pergolide on coc's subjective</outcome_measure>
      <outcome_measure>Effects of pergolide on cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-4</other_id>
      <other_id>R01-06234-4</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000215</url>
  </study>
  <study rank="327357">
    <nct_id>NCT00000214</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Direct cocaine effects (caridio, subjective)</outcome_measure>
      <outcome_measure>Interaction of coc/bup on cardio measures</outcome_measure>
      <outcome_measure>Ineraction of coc/bup on coc's subjective effects</outcome_measure>
      <outcome_measure>Effects of buprenorphine on cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-3</other_id>
      <other_id>R01DA006234</other_id>
      <other_id>R01-06234-3</other_id>
    </other_ids>
    <start_date>January 1992</start_date>
    <primary_completion_date>January 1993</primary_completion_date>
    <completion_date>January 1993</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 31, 2015</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000214</url>
  </study>
  <study rank="327358">
    <nct_id>NCT00000213</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fluoxetine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Direct cocaine effects</outcome_measure>
      <outcome_measure>Interaction of cocaine/fluox. on cardio measures</outcome_measure>
      <outcome_measure>Interaction of cocaine/fluox. on coc's subjective</outcome_measure>
      <outcome_measure>Effects of fluoxetine on cocaine craving</outcome_measure>
      <outcome_measure>Drug use during outpatient fluoxetine maintenance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-2</other_id>
      <other_id>R01DA006234</other_id>
      <other_id>R01-06234-2</other_id>
    </other_ids>
    <start_date>April 1990</start_date>
    <primary_completion_date>April 1991</primary_completion_date>
    <completion_date>April 1991</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 28, 2015</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000213</url>
  </study>
  <study rank="327359">
    <nct_id>NCT00000212</nct_id>
    <title>IV Cocaine Abuse: A Laboratory Model - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Desipramine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Amount cocaine self-administered</outcome_measure>
      <outcome_measure>Direct cocaine effects (cardiovascular, subjective</outcome_measure>
      <outcome_measure>Interaction of cocaine and DMI on cardio measures</outcome_measure>
      <outcome_measure>Interaction of cocaine/DMI on coc's subjective</outcome_measure>
      <outcome_measure>Effects of DMI on cocaine craving</outcome_measure>
      <outcome_measure>Drug use during outpatient DMI maintenance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York State Psychiatric Institute</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06234-1</other_id>
      <other_id>R01DA006234</other_id>
      <other_id>R01-06234-1</other_id>
    </other_ids>
    <start_date>July 1987</start_date>
    <primary_completion_date>July 1988</primary_completion_date>
    <completion_date>July 1988</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 31, 2015</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000212</url>
  </study>
  <study rank="327360">
    <nct_id>NCT00000211</nct_id>
    <title>Treatment Efficacy for Drug Abuse and AIDS Prevention - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Heroin Dependence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>26 Years</min_age>
    <max_age>41 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06116-2</other_id>
      <other_id>R18-06116-2</other_id>
    </other_ids>
    <start_date>September 1989</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>February 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000211</url>
  </study>
  <study rank="327361">
    <nct_id>NCT00000210</nct_id>
    <title>Treatment Efficacy for Drug Abuse and AIDS Prevention - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
      <condition>Heroin Dependence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>26 Years</min_age>
    <max_age>41 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06116-1</other_id>
      <other_id>R18-06116-1</other_id>
    </other_ids>
    <start_date>September 1989</start_date>
    <primary_completion_date>February 1996</primary_completion_date>
    <completion_date>February 1996</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>McLean Hospital, Dept. of Psychiatry, Belmont, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000210</url>
  </study>
  <study rank="327362">
    <nct_id>NCT00000209</nct_id>
    <title>Buprenorphine Dosing Interval - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opiate and cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Single</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-5</other_id>
      <other_id>R18-06082-5</other_id>
    </other_ids>
    <start_date>November 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000209</url>
  </study>
  <study rank="327363">
    <nct_id>NCT00000208</nct_id>
    <title>Methadone/Buprenorphine Cross-Over Study - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-4</other_id>
      <other_id>R18-06082-4</other_id>
    </other_ids>
    <start_date>February 1992</start_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 17, 2005</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000208</url>
  </study>
  <study rank="327364">
    <nct_id>NCT00000207</nct_id>
    <title>Multicenter Clinical Trial of Buprenorphine - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-3</other_id>
      <other_id>R18DA006082</other_id>
      <other_id>R18-06082-3</other_id>
    </other_ids>
    <start_date>May 1992</start_date>
    <primary_completion_date>April 1997</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000207</url>
  </study>
  <study rank="327365">
    <nct_id>NCT00000206</nct_id>
    <title>Clinical Rescue Protocol - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-2</other_id>
      <other_id>R18DA006082</other_id>
      <other_id>R18-06082-2</other_id>
    </other_ids>
    <start_date>April 1991</start_date>
    <primary_completion_date>August 2005</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>November 7, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000206</url>
  </study>
  <study rank="327366">
    <nct_id>NCT00000205</nct_id>
    <title>Buprenorphine Maintenance Protocol - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Opiate use</outcome_measure>
      <outcome_measure>Opiate craving</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-06082-1</other_id>
      <other_id>R18DA006082</other_id>
      <other_id>R18-06082-1</other_id>
    </other_ids>
    <start_date>October 1990</start_date>
    <primary_completion_date>March 1993</primary_completion_date>
    <completion_date>September 1993</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 11, 2016</last_update_posted>
    <locations>
      <location>Friends Research Institute, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000205</url>
  </study>
  <study rank="327367">
    <nct_id>NCT00000204</nct_id>
    <title>Buprenorphine Maintenance for Opioid Addicts - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05626-3</other_id>
      <other_id>R01DA005626</other_id>
      <other_id>R01-05626-3</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000204</url>
  </study>
  <study rank="327368">
    <nct_id>NCT00000203</nct_id>
    <title>Buprenorphine Maintenance for Opioid Addicts - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Withdrawal symptoms</outcome_measure>
      <outcome_measure>Psychological symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05626-2</other_id>
      <other_id>R01DA005626</other_id>
      <other_id>R01-05626-2</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000203</url>
  </study>
  <study rank="327369">
    <nct_id>NCT00000202</nct_id>
    <title>Buprenorphine Maintenance for Opioid Addicts - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Buprenorphine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05626-1</other_id>
      <other_id>R01DA005626</other_id>
      <other_id>R01-05626-1</other_id>
    </other_ids>
    <start_date>August 1988</start_date>
    <primary_completion_date>May 2006</primary_completion_date>
    <completion_date>May 2006</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>July 25, 2013</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000202</url>
  </study>
  <study rank="327370">
    <nct_id>NCT00000201</nct_id>
    <title>Pharmacological Modulation of Cocaine Effects - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-05196-1</other_id>
      <other_id>R01-05196-1</other_id>
    </other_ids>
    <completion_date>December 2001</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Johns Hopkins University (BPRU) Bayview Campus, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000201</url>
  </study>
  <study rank="327371">
    <nct_id>NCT00000200</nct_id>
    <title>Cocaine Effects in Humans: Physiology and Behavior - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methadone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Interaction of cocaine and meds on cardio</outcome_measure>
      <outcome_measure>Interaction of cocaine &amp; meds on coc's subjective</outcome_measure>
      <outcome_measure>Effects of medication on cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>19</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-03818-1</other_id>
      <other_id>R01-03818-1</other_id>
    </other_ids>
    <start_date>January 1997</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000200</url>
  </study>
  <study rank="327372">
    <nct_id>NCT00000199</nct_id>
    <title>Piracetam for Treatment of Cocaine Addiction, Phase II - 4</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Piracetam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Drug use</outcome_measure>
      <outcome_measure>Adverse effects</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00238-4</other_id>
      <other_id>K20DA000238</other_id>
      <other_id>K02-00238-4</other_id>
    </other_ids>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>March 30, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000199</url>
  </study>
  <study rank="327373">
    <nct_id>NCT00000198</nct_id>
    <title>Piracetam for Treatment of Cocaine Addiction - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Piracetam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pulse, blood pressure</outcome_measure>
      <outcome_measure>Adverse effects</outcome_measure>
      <outcome_measure>High, anxiety, withdrawal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>21 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00238-3</other_id>
      <other_id>K20DA000238</other_id>
      <other_id>K02-00238-3</other_id>
    </other_ids>
    <start_date>October 1996</start_date>
    <primary_completion_date>October 1997</primary_completion_date>
    <completion_date>October 1997</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>October 6, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000198</url>
  </study>
  <study rank="327374">
    <nct_id>NCT00000197</nct_id>
    <title>Propranolol for Treatment of Cocaine Addiction - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Propranolol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine withdrawal</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
      <outcome_measure>Mood and anxiety</outcome_measure>
      <outcome_measure>Clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute on Drug Abuse (NIDA)</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>49 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00238-2</other_id>
      <other_id>K20DA000238</other_id>
    </other_ids>
    <start_date>January 1987</start_date>
    <primary_completion_date>January 2002</primary_completion_date>
    <completion_date>January 2002</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>January 12, 2017</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000197</url>
  </study>
  <study rank="327375">
    <nct_id>NCT00000196</nct_id>
    <title>Neurobiology of Opioid Dependence: 5 - 5</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, physiological, neuroendocrine response to yohimbine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-5</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-5</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>June 3, 2015</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000196</url>
  </study>
  <study rank="327376">
    <nct_id>NCT00000195</nct_id>
    <title>Neurobiology of Opioid Dependence: 4 - 4</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, physiological, neuroendocrine response to yohimine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-4</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-4</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000195</url>
  </study>
  <study rank="327377">
    <nct_id>NCT00000194</nct_id>
    <title>Neurobiology of Opioid Dependence: 3 - 3</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cycloserine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, subjective, measures of naloxone-preci</outcome_measure>
      <outcome_measure>Phsyiological, neuroendocrine measures of naloxone</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-3</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-3</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 6, 2016</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000194</url>
  </study>
  <study rank="327378">
    <nct_id>NCT00000193</nct_id>
    <title>Neurobiology of Opioid Dependence: 2 - 2</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gamma hydroxybutyric</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, subjective, measures of naloxone-preci</outcome_measure>
      <outcome_measure>Phsyiological, neuroendocrine measures of naloxone</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-2</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-2</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 7, 2015</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000193</url>
  </study>
  <study rank="327379">
    <nct_id>NCT00000192</nct_id>
    <title>Neurobiology of Opioid Dependence: 1 - 1</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lamotrigine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Behavioral, subjective, measures of naloxone-precipitated opiate withdrawal</outcome_measure>
      <outcome_measure>Phsyiological, neuroendocrine measures of naloxone-precipitated opiate withdrawal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Masking: Double</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00191-1</other_id>
      <other_id>K20DA000191</other_id>
      <other_id>K20-00191-1</other_id>
    </other_ids>
    <start_date>January 1993</start_date>
    <primary_completion_date>January 1998</primary_completion_date>
    <completion_date>January 1998</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>August 7, 2015</last_update_posted>
    <locations>
      <location>VA Connecticut Healthcare System, New Haven, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000192</url>
  </study>
  <study rank="327380">
    <nct_id>NCT00000191</nct_id>
    <title>Carbamazepine Treatment for Cocaine Dependence - 5</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carbamazepine</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>51 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-5</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-5</other_id>
    </other_ids>
    <start_date>January 1991</start_date>
    <primary_completion_date>February 1994</primary_completion_date>
    <completion_date>February 1994</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000191</url>
  </study>
  <study rank="327381">
    <nct_id>NCT00000190</nct_id>
    <title>Cocaine in Parotid Saliva, Blood and Urine - 4</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Parotid Gland</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine &amp; benzoylecgonine content in saliva, plasma, &amp; urine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-4</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-4</other_id>
    </other_ids>
    <start_date>January 1991</start_date>
    <primary_completion_date>February 1992</primary_completion_date>
    <completion_date>February 1992</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000190</url>
  </study>
  <study rank="327382">
    <nct_id>NCT00000189</nct_id>
    <title>Gepirone vs Placebo in Treatment of Cocaine Dependence - 3</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gepirone</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-3</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-3</other_id>
    </other_ids>
    <start_date>January 1990</start_date>
    <primary_completion_date>February 1991</primary_completion_date>
    <completion_date>February 1991</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000189</url>
  </study>
  <study rank="327383">
    <nct_id>NCT00000188</nct_id>
    <title>Selegiline in Treatment of Cocaine Dependence - 2</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selegiline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Retention</outcome_measure>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-2</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-2</other_id>
    </other_ids>
    <start_date>September 1994</start_date>
    <primary_completion_date>October 1995</primary_completion_date>
    <completion_date>October 1995</completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>PDVAMC Treatment Research Center, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000188</url>
  </study>
  <study rank="327384">
    <nct_id>NCT00000187</nct_id>
    <title>Ritanserin in Treatment of Cocaine Dependence - 1</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cocaine-Related Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ritanserin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cocaine use</outcome_measure>
      <outcome_measure>Cocaine craving</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>National Institute on Drug Abuse (NIDA)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>28 Years</min_age>
    <max_age>47 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDA-00144-1</other_id>
      <other_id>3R01DA012268</other_id>
      <other_id>K20-00144-1</other_id>
    </other_ids>
    <start_date>July 1992</start_date>
    <primary_completion_date>June 1994</primary_completion_date>
    <study_first_posted>September 21, 1999</study_first_posted>
    <last_update_posted>May 28, 2015</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00000187</url>
  </study>
  <study rank="327385">
    <nct_id>NCT00004640</nct_id>
    <title>&quot;Clinical Trials to Enhance Elders' Oral Health&quot; (&quot;TEETH&quot;)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tooth Loss</condition>
      <condition>Periodontal Disease</condition>
      <condition>Tooth Decay</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chlorhexidine rinse</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>regular rinsing with chlorhexidine is effective method for reducing the incidence of tooth loss in low income older adults.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>National Institute of Dental and Craniofacial Research (NIDCR)</collaborator>
      <collaborator>Colgate Palmolive</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1101</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDCR-008</other_id>
      <other_id>R01DE012215</other_id>
    </other_ids>
    <start_date>May 1998</start_date>
    <primary_completion_date>May 2008</primary_completion_date>
    <completion_date>October 2008</completion_date>
    <study_first_posted>September 20, 1999</study_first_posted>
    <last_update_posted>June 20, 2012</last_update_posted>
    <locations>
      <location>University of Washington, Seattle, Washington, United States</location>
      <location>University of British Columbia, Vancouver, British Columbia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004640</url>
  </study>
  <study rank="327386">
    <nct_id>NCT00004639</nct_id>
    <title>Cleft Palate Surgery and Speech Development</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cleft Lip</condition>
      <condition>Cleft Palate</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Furlow double z-plasty palatoplasty palate repair</intervention>
      <intervention type="Procedure">Von Langenbeck palatoplasty palate repair</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Velopharyngeal function for speech was identified to be better for patients who received the Furlow double opposing z-palatoplasty procedure than patients who received the von Langenbeck procedure, as determined by the Cul-de-Sac Test of Hypernasality.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Florida</lead_sponsor>
      <collaborator>University of Sao Paulo</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>475</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIDCR-010</other_id>
      <other_id>R01DE010437</other_id>
    </other_ids>
    <start_date>February 1996</start_date>
    <primary_completion_date>March 2006</primary_completion_date>
    <completion_date>April 2007</completion_date>
    <study_first_posted>September 20, 1999</study_first_posted>
    <last_update_posted>September 20, 2011</last_update_posted>
    <locations>
      <location>University of Florida, Gainesville, Florida, United States</location>
      <location>Hospital for Rehabilitation of Craniofacial Anomalies (USP-HRAC), Bauru, Sao Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT00004639</url>
  </study>
</search_results>
